topic0
Estrogen [horm, phsu, strd] 0.00525856313097
C-reactive protein [aapp, imft] 0.00341820400968
placebo [topp] 0.00333081651095
Men [popg] 0.00323011686547
N NOS [aapp, imft] 0.00313872700995
Stroke [dsyn] 0.0028750637851
Recent [tmco] 0.00247585271365
Diabetes [dsyn] 0.00246289315586
mg% [qnco] 0.0023999446975
Myocardial Infarction [dsyn] 0.00231891565621
Similar [qlco] 0.00223881998824
Individual [popg] 0.00222317726599
Menopause [phsf] 0.00219874187396
Oral [spco] 0.00219778948654
randomized [resa] 0.00218273339602
vascular [bpoc] 0.00215380215999
Subject [grup] 0.00206009078161
Benefit [qnco] 0.00204276700824
Plasma [bdsu] 0.00197339226324
Blood Pressure [orgf] 0.00196347499923
Receive [qlco] 0.00191525909199
PREVENT [phsu] 0.00182590234153
Raloxifene [orch, phsu] 0.00181957833869
Incidence [qnco] 0.00181039909866
Confidence Interval [qnco] 0.00178512765341
coronary [bpoc] 0.00171520630319
Association [menp] 0.00170837490141
Early [tmco] 0.00168703124149
Drug [phsu] 0.00167466087826
Received [qlco] 0.00167170942344
Large [qnco] 0.00166643005302
Decreased [qnco] 0.00165851377602
Users [humn] 0.00165049459238
Cholesterol [bacs, strd] 0.00164897823706
Statins [orch, phsu] 0.00163820414681
Old [tmco] 0.00162758089071
Overall [inpr] 0.00162499793591
Measured [qlco] 0.00160614669764
Survival [acty] 0.00155130436928
Smoking [inbe] 0.00150363569838
Purpose [ftcn] 0.00149911884368
Decrease [qlco] 0.00149181474188
Progestin [horm, phsu, strd] 0.00148629683097
Combined [qlco] 0.00148397883464
Cancer [neop] 0.00146909378436
function [phsf] 0.00145729661855
Osteoporosis [dsyn] 0.00145471687626
Concentrations [menp] 0.00145191289552
Non [ftcn] 0.00144888770057
Response [orga] 0.0014440071386
Breast Cancer [neop] 0.00144307965824
Atherosclerosis [dsyn] 0.00141319899784
Marker [clna] 0.00141082559415
Range [qnco] 0.00141023776346
Profile [lbpr] 0.00138429520812
Serum [bdsu] 0.00137447483168
Evaluated [ftcn] 0.00137376837192
IMPACT [gngm] 0.00137215553974
Change [ftcn] 0.00137168002351
R- [spco] 0.00137085841131
Therapeutic [topp] 0.00135362718063
weeks [tmco] 0.00134676044652
Drugs [phsu] 0.00133846939045
Acute myocardial infarction [dsyn] 0.00133339876575
Cardiac [bpoc] 0.00133028587734
Several [qnco] 0.00132652359789
Lipid [lipd] 0.00131413851493
Possible [qlco] 0.0013096528966
Cases [ftcn] 0.00130827793254
Death [orgf] 0.00130460983808
High Risk [qlco] 0.00130258186466
Assess [acty] 0.00130164435152
Common [qnco] 0.00129907438142
Current [tmco] 0.00129245240097
Available [ftcn] 0.0012831442001
Aged [orga] 0.00126825116294
Elevated [qlco] 0.001249287382
Body Mass Index [diap] 0.0012387069907
Hormone [horm] 0.00123792269395
Predictor [idcn] 0.0012327118515
Conduct [inbe] 0.00122639358178
coronary artery disease [dsyn] 0.0012113141116
Events [evnt] 0.00120921898455
ischaemic heart disease [dsyn] 0.00120236726906
WHI [inpr] 0.00119998995847
Estradiol [horm, phsu, strd] 0.00119695580501
Heart disease [dsyn] 0.0011946466704
Hormone Therapy [topp] 0.00118772547489
Plus [qlco] 0.00117090296236
findings [ftcn] 0.00117084909552
HRT [topp] 0.00116812236434
acute [tmco] 0.00115140895859
Dose [qnco] 0.00114772760436
History [ocdi] 0.00113335082316
Specific [qlco] 0.00112462426608
Alone [qnco] 0.00112381286142
Daily [tmco] 0.00112047714283
practice [menp] 0.00111519839601
Well [qlco] 0.00111407899816
symptoms [ftcn] 0.00111167277002
development [phsf] 0.0010987737566
Model [inpr] 0.00108550061025
low [qlco] 0.0010714661517
Elderly [popg] 0.001068376809
Identified [qlco] 0.00106574868918
lowering [spco] 0.00106571958307
Complications [patf] 0.00106479416035
mg dl [qnco] 0.00106131367341
Information [idcn] 0.00105840166364
Equal [qlco] 0.00105773863277
Life [idcn] 0.00105276328705
Agent [chvf] 0.00105268955939
Statin [orch, phsu] 0.00105258798265
Total Cholesterol [lbpr] 0.00105112091467
Initiative [menp] 0.00104718322438
Previous [tmco] 0.00104528045276
Combination [qlco] 0.00104518167174
intervention [hlca] 0.00104044489561
Heart [bpoc] 0.00103497579095
Reported [inpr] 0.00103337005483
Endothelial [tisu] 0.0010235203256
Make [ftcn] 0.00101968559034
variables [qlco] 0.00101376795161
Take [hlca] 0.00101271988363
Dependent [qlco] 0.00101059727106
Induced [ftcn] 0.00100666715489
medroxyprogesterone acetate [horm, phsu, strd] 0.00100233267967
Likely [qlco] 0.00100046940757
considered [idcn] 0.000998711043852
Morbidity [qnco] 0.000997441220053
Parameters [fndg] 0.000991071441639
Young [tmco] 0.00098692978689
Improvement [cnce] 0.000985847949249
Prevalence [qnco] 0.000977388764732
Target [ftcn] 0.00097381347881
Addition [ftcn] 0.000967118054929
Transdermal [ftcn] 0.000963308429076
Clinical Trials [resa] 0.000954128056671
median [spco] 0.00095053073093
Administration [ocac] 0.00094792769081
Safety [hcpp] 0.000945456680675
participants [popg] 0.000941510320344
Benefits [qnco] 0.000940564512523
cardiovascular risk factor [dsyn] 0.000939448099359
Quality [qlco] 0.000938341515587
investigated [ftcn] 0.000933311110746
Article [inpr] 0.000930260452925
Following [tmco] 0.000924579312312
Diagnosis [fndg] 0.000923085073695
Primary [qlco] 0.000912473378491
heart rate [clna] 0.000909297220039
Concentration [menp] 0.000906832179849
Needed [qlco] 0.000906205432556
Presence [topp] 0.000905591391394
Fasting [fndg] 0.00090006280223
Fibrinogen [aapp, bacs, phsu] 0.00090000187244
Independent [idcn] 0.000899665974652
Compare [acty] 0.00089840561888
Percent [qnco] 0.00089650728238
Affect [menp] 0.000889213237521
radiotherapy [inpr] 0.000888951669843
Four [qnco] 0.000886522448646
Need [qlco] 0.000879732811954
Risks [qlco] 0.000876236592993
Cost [qnco] 0.000876092037233
Dyslipidaemia [dsyn] 0.000875846318903
Ratio [qnco] 0.000872363321321
Atrial Fibrillation [patf] 0.000865918815397
Female [fndg] 0.000865911325852
Medical [ftcn] 0.00086358578635
Assessed [acty] 0.000863236762888
cardiovascular events [fndg] 0.00086277192238
Index [inpr] 0.000852183882792
tibolone [phsu, strd] 0.000851965137748
GIVEN [cnce] 0.000849559132863
Null [qnco] 0.000843600106956
APPEAR [qlco] 0.000843069736477
Sex [orgf] 0.000841542184788
setting [ftcn] 0.000833250414897
Published [ocac] 0.000832047572574
mediated [socb] 0.000831171764926
Future [tmco] 0.000831092123682
Increasing [ftcn] 0.000829410304509
Cholesterol, LDL [bacs, strd] 0.000828829065819
objectives [inpr] 0.000825588870765
condition [dsyn] 0.000825528429069
Estrogens [horm, phsu, strd] 0.000825199946745
Risk factor [qnco] 0.000825019633098
In [qnco] 0.000823417911058
Exercise [dora] 0.000823002254745
High Density Lipoprotein Cholesterol [bacs, lipd] 0.000822108363489
national [inpr] 0.000818812626483
Contribute [acty] 0.000815073458249
Triglycerides [bacs, lipd] 0.000813142658107
Low Density Lipoprotein Cholesterol [bacs, strd] 0.000811068436242
Guidelines [inpr] 0.000809902670978
Strong [qlco] 0.000808859002636
Known [qlco] 0.000807791377417
Drug Therapy [topp] 0.000806543766665
Diet [food] 0.000805888340577
experience [menp] 0.000793265313923
Type [qlco] 0.000789192656269
Obesity [dsyn] 0.000786766092951
Values [qlco] 0.000785235482119
Relationship [qlco] 0.000783658585867
H+ [elii] 0.000783414991177
Flow [npop] 0.000778956524004
progression [patf] 0.000776684237434
Concern [idcn] 0.000773499927768
Inflammation [patf] 0.000772020483087
soy [food] 0.00077192294174
Relative [famg] 0.000770154716024
Endothelium [tisu] 0.000769734860654
Isoflavones [orch, phsu] 0.000769269893286
Associations [menp] 0.000765307832504
Secondary Prevention [topp] 0.000765233220973
Equine [mamm] 0.000764827995168
Established [qlco] 0.000762711630241
Five [qnco] 0.000761512312008
Examined [fndg] 0.000756190832478
Diseases [dsyn] 0.000755527090147
Reducing [qlco] 0.000751116342239
Interaction [ftcn] 0.000746270873371
I- [inch] 0.000744785990806
Currently [tmco] 0.000732286149745
Beta [plnt] 0.000731727900893
Same [qlco] 0.00072869439725
Status [qlco] 0.000728323677824
Case [ftcn] 0.00072745736249
placebo-controlled [resa] 0.000726822656756
Recommended [idcn] 0.000721999709825
DOUBLE BLIND [resa] 0.000720041048193
Continuous [idcn] 0.000719528330668
Main [qlco] 0.000718751226622
Better [qlco] 0.000717714509053
Life Style [socb] 0.000717414135045
Recently [tmco] 0.000717298158546
Issue [fndg] 0.000716973057388
???lead [elii, hops] 0.000716280932325
homocysteine [aapp, bacs] 0.000715337171951
General [spco] 0.000715334193608
Support [medd] 0.000710945898851
Provide [acty] 0.000710327556634
weight [orga] 0.000707037621917
Direct [qlco] 0.00070647144766
Assessment [hlca] 0.000705435687063
Improved [qlco] 0.000703570942184
Inflammatory [ftcn] 0.000702464194193
Mechanisms [ftcn] 0.000698602043997
rats [mamm] 0.000697937718084
Estrogen Replacement Therapy [topp] 0.00069569544826
Dietary [food] 0.00069323900054
Appropriate [qlco] 0.000685424808442
Now [tmco] 0.000681637232364
Human [humn] 0.000681338116357
Score [qnco] 0.000677872990471
Average [qnco] 0.000677185609017
Involved [ftcn] 0.000676786970503
measurements [ftcn] 0.00067514755431
Ireland [geoa] 0.00067426474965
Question [inpr] 0.000673781020814
Sample [sbst] 0.000672795092305
Low dose [qnco] 0.000669115149896
Obtained [ftcn] 0.000667628535422
Odds Ratio [qnco] 0.000665928088145
Occur [acty] 0.000664241118057
hypertensive [fndg] 0.000663407467614
Severe [qlco] 0.000662987419381
Additional [ftcn] 0.00066286646743
prospective [resa] 0.000662686646516
Aspirin [orch, phsu] 0.00066233888652
Atherogenesis [patf] 0.000661224669832
LTD [ortf] 0.000660203721011
account [idcn] 0.000659563714579
chronic [tmco] 0.000658043470571
Hazard Ratio [qnco] 0.000657951886551
Represent [acty] 0.000657339829059
influential [idcn] 0.000657114499039
mice [mamm] 0.000653897104152
Small [qnco] 0.000653135592224
secondary [neop] 0.000649946750147
Alternative [cnce] 0.000649406267058
Insulin [aapp, horm, phsu] 0.000649260742883
Multiple [qnco] 0.000648789032333
Few [qnco] 0.00064599228308
III [inpr] 0.000645195004893
Late [tmco] 0.000644559716216
Relative Risk [qnco] 0.000641628852575
activity [dora] 0.000641082626648
investigate [ftcn] 0.000640056393841
Correlated [qlco] 0.000638268867826
Limited [ftcn] 0.000638231415354
Evaluation [ftcn] 0.00063671991261
mg day [qnco] 0.000636076158957
Heart failure [dsyn] 0.000635002411323
Treatments [topp] 0.000633600522522
System [ftcn] 0.000633455911768
premenopausal [tmco] 0.000631726479594
Seen [qlco] 0.000631596291779
Adjusted [ftcn] 0.000626972401837
Relevant [qlco] 0.000625343838048
Surgery [bmod] 0.000621629249326
Moderate [qlco] 0.000621155107024
Progesterone [horm, phsu, strd] 0.000620029194813
Frequently [tmco] 0.000619521235269
High density lipoprotein [aapp, bacs, lipd] 0.000619183579223
Physicians [prog] 0.000619107839737
Hospital [hcro, mnob] 0.000618837208566
Long [qlco] 0.000617774009748
Venous malformation [anab] 0.000617631940937
Prognostic Factor [clna] 0.000616457362009
Very [qlco] 0.000615077056068
patient care [hlca] 0.00061449234586
Copyright [inpr] 0.000613493284817
Expression [topp] 0.000613359877853
Literature [inpr] 0.000610784577026
strategies [menp] 0.00060968953285
C-reactive protein level [lbpr] 0.00060927350882
statistically significant [qnco] 0.000608905511418
deaths [orgf] 0.000607463102046
Various [irda] 0.000603554512052
Leading [tmco] 0.000602387600327
strategy [menp] 0.000602095273998
Help [socb] 0.000598430613694
Measure [qnco] 0.000597835372991
Part [spco] 0.0005975641768
Low density lipoprotein [aapp, bacs, lipd] 0.000596366354393
Single [popg] 0.000592205937734
Beta-Blockers [phsu] 0.000591742587096
Control Group [grup] 0.000588898297928
Hypothesis [idcn] 0.000588002555642
Duration [tmco] 0.000587773040402
Variability [cnce] 0.000586735466715
Blood [tisu] 0.000583405405129
Observational Study [resa] 0.000582162845023
Initial [tmco] 0.000581842755523
Comparison [acty] 0.000579797305297
Cost Effectiveness [qnco] 0.000576910266208
Adult [aggp] 0.000576408747173
diabetic [fndg] 0.000573456026646
Inhibition [menp] 0.000572954670739
Physical activity [dora] 0.000568705421082
Bone Mineral Density [clna] 0.000567462049805
Children [aggp] 0.000567219607861
Report [inpr] 0.000566419873542
procedures [inpr] 0.000563643571056
Negative [qlco] 0.000562891247357
Approach [spco] 0.000561577595255
Primary Prevention [topp] 0.000560923201234
Lipid-lowering therapy [topp] 0.000559926752808
Adults [aggp] 0.000559910076174
Exist [cnce] 0.000559292508961
mmHg [qnco] 0.000558343362453
regimens [inpr] 0.000556710152188
search [inpr] 0.000554965875675
Education [edac] 0.000554806308445
Gender [orga] 0.00055327765872
Conjugated estrogen [horm, phsu, strd] 0.000549442683956
Short-term [tmco] 0.000548095530869
Systemic [ftcn] 0.000547723195583
Triglyceride [bacs, lipd] 0.000543742552141
cee [orch] 0.000541541389533
rosuvastatin [orch, phsu] 0.000541326533917
Magnetic Resonance Imaging [diap] 0.000541244091768
Calcium [bacs, elii, phsu] 0.000540811303382
Sclerotherapy [topp] 0.000537202564503
Lp(a) [aapp, bacs] 0.000535944352422
Favorable [qlco] 0.000535842475041
Doses [qnco] 0.000535756470475
Arterial [bpoc] 0.00053478812868
atorvastatin [orch, phsu] 0.000531412560022
Science [ocdi] 0.000529983564173
menopausal symptoms [sosy] 0.000529318412945
Ischaemic [ftcn] 0.000528927563632
Triglyceride level [lbtr] 0.000525934092093
Third [qnco] 0.000525866262455
Age-Years [tmco] 0.000525120643348
Chemoprevention [topp] 0.000524899955179
Action [ftcn] 0.000524185198736
Screening [hlca] 0.00052304504644
Determinant [ftcn] 0.000519178429103
Class [inpr] 0.000518267447799
Replacement [topp] 0.000517191947398
Genotype [orga] 0.00051437479182
Hospitalization [hlca] 0.000513928148816
Survivors [podg] 0.000513305629431
Method [inpr] 0.000512918742454
Systolic [tmco] 0.00051202586088
conclude [bodm, orch] 0.000508578434612
Characteristics [qlco] 0.0005083591193
Measures [qnco] 0.000507718310517
Protein [aapp, bacs] 0.000507610783551
Adjustment [inbe] 0.000506783364672
Select [acty] 0.000506717828534
Estimated [qnco] 0.000506610558781
Prognosis [hlca] 0.000504074080164
Second [qnco] 0.000503321093221
Protection [fndg] 0.000503291210675
Assigned [ftcn] 0.000501496547675
End [spco] 0.000501421279384
topic1
Estrogen [horm, phsu, strd] 0.00432820019042
N NOS [aapp, imft] 0.00361115883271
Myocardial Infarction [dsyn] 0.00290158553727
Men [popg] 0.00275795086106
C-reactive protein [aapp, imft] 0.00271281259071
Oral [spco] 0.00265123430049
randomized [resa] 0.00253680456093
placebo [topp] 0.00231346167474
Association [menp] 0.00230333856154
Recent [tmco] 0.00230270729746
Stroke [dsyn] 0.00229983234949
Individual [popg] 0.00220772652316
Diabetes [dsyn] 0.00216150588028
Non [ftcn] 0.00216046385162
mg% [qnco] 0.00197341530564
Measured [qlco] 0.00195367811783
R- [spco] 0.00187270090538
Decrease [qlco] 0.0018163105843
Benefit [qnco] 0.00177285943283
Received [qlco] 0.00174176727454
Lipid [lipd] 0.00172094363238
Current [tmco] 0.00171334135303
Receive [qlco] 0.0017095511159
Plasma [bdsu] 0.00166825473446
Statins [orch, phsu] 0.00164995903226
Early [tmco] 0.00164498643181
Atherosclerosis [dsyn] 0.00162802217505
Cardiac [bpoc] 0.00161738761789
Survival [acty] 0.00161568575852
findings [ftcn] 0.0016112371807
Decreased [qnco] 0.00160906838038
Dose [qnco] 0.001608541528
Induced [ftcn] 0.00159673282238
Menopause [phsf] 0.00159390164228
Death [orgf] 0.00159356080757
Plus [qlco] 0.00159069154845
Blood Pressure [orgf] 0.00157608672859
Subject [grup] 0.00154638842402
Cases [ftcn] 0.00152310760764
Raloxifene [orch, phsu] 0.00149189697509
Similar [qlco] 0.00148841874211
development [phsf] 0.00148044902429
Confidence Interval [qnco] 0.0014792310821
Concentrations [menp] 0.00147577257527
Following [tmco] 0.0014363672897
Administration [ocac] 0.0014224200925
Heart disease [dsyn] 0.00141802096303
Marker [clna] 0.00141582289321
Complications [patf] 0.00141552792254
Users [humn] 0.00141116602644
Change [ftcn] 0.00141071794199
Breast Cancer [neop] 0.00140469463137
Acute myocardial infarction [dsyn] 0.00139305807887
acute [tmco] 0.0013914341765
symptoms [ftcn] 0.00139112620105
mg dl [qnco] 0.00138016058719
Drugs [phsu] 0.00137432932898
Cholesterol [bacs, strd] 0.00137112365063
weeks [tmco] 0.00137105456745
coronary [bpoc] 0.00136974373623
Endothelial [tisu] 0.00136470828395
Profile [lbpr] 0.00136113041118
Total Cholesterol [lbpr] 0.00135902212748
Incidence [qnco] 0.00134709493047
Take [hlca] 0.00133504397563
Therapeutic [topp] 0.00133356238509
Old [tmco] 0.00133232977659
Elderly [popg] 0.00132877503645
lowering [spco] 0.00132107801197
Agent [chvf] 0.00131474399719
Body Mass Index [diap] 0.0013137623321
History [ocdi] 0.00130461553234
Several [qnco] 0.0012942688136
function [phsf] 0.00129345967234
Overall [inpr] 0.00127674965575
Specific [qlco] 0.00127125500895
Target [ftcn] 0.00126669087262
Equal [qlco] 0.0012646859905
Statin [orch, phsu] 0.00125329530557
Common [qnco] 0.00123787380156
Range [qnco] 0.00123621054618
considered [idcn] 0.00122819645688
Alone [qnco] 0.00120984883915
Response [orga] 0.00120977144799
Combined [qlco] 0.0011968344305
WHI [inpr] 0.00119264947309
Conduct [inbe] 0.00118790271197
Assess [acty] 0.00117585674686
Available [ftcn] 0.00117184005078
Estradiol [horm, phsu, strd] 0.00117161357253
Values [qlco] 0.00116903818811
Drug [phsu] 0.00116739921138
Smoking [inbe] 0.00116261721848
Article [inpr] 0.00115646219436
Aged [orga] 0.00115224398864
Additional [ftcn] 0.0011465234602
medroxyprogesterone acetate [horm, phsu, strd] 0.00114164050508
Secondary Prevention [topp] 0.0011323832132
IMPACT [gngm] 0.00113204694676
PREVENT [phsu] 0.00111906581954
Prevalence [qnco] 0.00111900277479
Increasing [ftcn] 0.0011172039195
Mechanisms [ftcn] 0.00111433135588
Assessed [acty] 0.00111085349009
Presence [topp] 0.00111028349743
vascular [bpoc] 0.00110901968429
Improvement [cnce] 0.00110780018616
ischaemic heart disease [dsyn] 0.00110770364139
Reported [inpr] 0.00110566712314
Clinical Trials [resa] 0.00110029039616
Evaluated [ftcn] 0.00109987872866
Events [evnt] 0.00109712817754
Sex [orgf] 0.00109001877895
Elevated [qlco] 0.00109000524448
Identified [qlco] 0.00108984095236
Medical [ftcn] 0.00108286785686
Independent [idcn] 0.00107072700587
Transdermal [ftcn] 0.00107010440591
low [qlco] 0.00106677173666
Future [tmco] 0.0010591735443
practice [menp] 0.00105696913147
Addition [ftcn] 0.00104998600778
Serum [bdsu] 0.00104873627882
Hormone Therapy [topp] 0.00103636093686
Cancer [neop] 0.00103523127272
Hormone [horm] 0.00103114629707
Life [idcn] 0.00101534764028
Make [ftcn] 0.00101094101956
Null [qnco] 0.00100828461483
Likely [qlco] 0.00100043316965
Drug Therapy [topp] 0.000997036874175
Combination [qlco] 0.000989432650305
Well [qlco] 0.000989320351293
mediated [socb] 0.00098509401589
Initiative [menp] 0.000983344508479
Purpose [ftcn] 0.00098152100195
radiotherapy [inpr] 0.000979998517673
Safety [hcpp] 0.00097633575007
Benefits [qnco] 0.000976009023262
Estrogen Replacement Therapy [topp] 0.000973623358284
participants [popg] 0.000971105074369
Diagnosis [fndg] 0.000969704217798
coronary artery disease [dsyn] 0.00096371126269
High Risk [qlco] 0.000961183524648
Need [qlco] 0.00095936761178
LTD [ortf] 0.000952394841443
Morbidity [qnco] 0.000952239316747
Quality [qlco] 0.000946826163003
Dependent [qlco] 0.000941038163225
Model [inpr] 0.000940926920965
Progestin [horm, phsu, strd] 0.000937908080413
Affect [menp] 0.000937801424466
High Density Lipoprotein Cholesterol [bacs, lipd] 0.000937757892868
Possible [qlco] 0.000935010258546
Predictor [idcn] 0.000932224803376
strategies [menp] 0.000931168038974
I- [inch] 0.000930556644428
influential [idcn] 0.000927589972341
Concentration [menp] 0.00092462861674
Large [qnco] 0.000916609238083
variables [qlco] 0.000915242461949
intervention [hlca] 0.000913519940747
Aspirin [orch, phsu] 0.000909181528047
Risk factor [qnco] 0.000907767392372
Guidelines [inpr] 0.000905177525965
Care [acty] 0.000903963717324
Endothelium [tisu] 0.000903327335626
In [qnco] 0.000898811736321
Inflammation [patf] 0.000896044945649
heart rate [clna] 0.000895392203533
GIVEN [cnce] 0.000894520296487
Osteoporosis [dsyn] 0.000893404475186
Triglycerides [bacs, lipd] 0.000891193662756
Young [tmco] 0.000889607074351
Primary [qlco] 0.000889314926204
Adjusted [ftcn] 0.000889221590637
Diet [food] 0.000875380551997
APPEAR [qlco] 0.000870416615031
Risks [qlco] 0.000867287863791
Low Density Lipoprotein Cholesterol [bacs, strd] 0.000861929270965
Heart failure [dsyn] 0.000855092722897
Improved [qlco] 0.000851879260223
Estrogens [horm, phsu, strd] 0.000841976410399
Frequently [tmco] 0.000840443174479
Ratio [qnco] 0.00083889626603
cardiovascular risk factor [dsyn] 0.000837730373174
Type [qlco] 0.000835894155326
tibolone [phsu, strd] 0.000830850946827
Average [qnco] 0.000829752954874
Parameters [fndg] 0.000827284404887
Obesity [dsyn] 0.000825762860358
Odds Ratio [qnco] 0.000823809948047
Relative Risk [qnco] 0.000818974015956
Multiple [qnco] 0.000818694796622
Insulin [aapp, horm, phsu] 0.000818098366996
Inflammatory [ftcn] 0.000812978901249
H+ [elii] 0.000811384121761
Sample [sbst] 0.000810532357401
experience [menp] 0.000808669210732
Main [qlco] 0.000807961567406
Needed [qlco] 0.000805589653947
Severe [qlco] 0.000805565273081
Cohort [popg] 0.000802575045121
investigated [ftcn] 0.00080101171223
objectives [inpr] 0.000796572569253
Information [idcn] 0.000792107899489
Flow [npop] 0.000791006716849
Compare [acty] 0.000785377526775
Four [qnco] 0.000785333476194
Daily [tmco] 0.000783925151505
activity [dora] 0.000783738953966
Provide [acty] 0.000778991123008
HRT [topp] 0.000778462462033
Ireland [geoa] 0.000775168262395
recommendations [idcn] 0.000773430738025
national [inpr] 0.000768143782395
Surgery [bmod] 0.000760271342398
Heart [bpoc] 0.000759187085709
diabetic [fndg] 0.000757565707171
Copyright [inpr] 0.000756900758049
Published [ocac] 0.000756182764045
Human [humn] 0.000756131492023
Cholesterol, LDL [bacs, strd] 0.00075493554842
Fasting [fndg] 0.000748031153799
C-reactive protein level [lbpr] 0.000746767414512
month [tmco] 0.000745274965474
Issue [fndg] 0.00074518983213
Examined [fndg] 0.000741153638856
Support [medd] 0.000740949890822
Known [qlco] 0.000739091900949
Female [fndg] 0.000736078374836
Atrial Fibrillation [patf] 0.00073522033302
System [ftcn] 0.000733902374786
Recommended [idcn] 0.000730709405962
Approach [spco] 0.000729030628638
lesions [fndg] 0.000728723248101
Conjugated estrogen [horm, phsu, strd] 0.000727276944126
Duration [tmco] 0.000722908308563
Established [qlco] 0.000720483287067
Concern [idcn] 0.000714113323729
Index [inpr] 0.000712236480468
prospective [resa] 0.000709688554487
Variability [cnce] 0.000709124483569
Sclerotherapy [topp] 0.0007077600311
Venous malformation [anab] 0.000706974878451
Exercise [dora] 0.00070664452272
Equine [mamm] 0.000703292278412
Contribute [acty] 0.00070092372
Fibrinogen [aapp, bacs, phsu] 0.000697648612441
Status [qlco] 0.000696286202066
Part [spco] 0.000694298456951
Relationship [qlco] 0.000694033706733
Short-term [tmco] 0.000693848263979
homocysteine [aapp, bacs] 0.000693407584811
Prognosis [hlca] 0.000692059400705
Event [evnt] 0.000688941732925
premenopausal [tmco] 0.00068613362798
Evaluation [ftcn] 0.000684931662391
mmHg [qnco] 0.000682286297778
Children [aggp] 0.000679247510353
Gender [orga] 0.000677498196758
Case [ftcn] 0.000675223715359
Cost [qnco] 0.000673803440038
rats [mamm] 0.000672568561199
Dietary [food] 0.000670675964815
Action [ftcn] 0.000669628354292
Percent [qnco] 0.000662756152218
Occur [acty] 0.000662310735991
account [idcn] 0.000662247316579
Familial hypercholesterolaemia [dsyn] 0.000660716149602
Observational Study [resa] 0.000660284071891
Relative [famg] 0.000658724882311
Assessment [hlca] 0.000655310400013
Various [irda] 0.000655268320434
investigate [ftcn] 0.000654432564382
Replacement [topp] 0.000652833486178
Expression [topp] 0.000652710591641
reductions [npop] 0.000650816279949
Single [popg] 0.000650178652844
Late [tmco] 0.000649454479419
Five [qnco] 0.000649066624621
median [spco] 0.000648340486826
Mechanism [ftcn] 0.000645017115622
rosuvastatin [orch, phsu] 0.000639681415428
Seen [qlco] 0.000639680570544
cardiovascular events [fndg] 0.000639252144842
Initial [tmco] 0.000638864551139
Small [qnco] 0.000637608233949
Question [inpr] 0.000637208581497
Control Group [grup] 0.000637199027154
Select [acty] 0.000630424573
Previous [tmco] 0.00062952946163
Obtained [ftcn] 0.000624783976422
Hypercholesterolaemia [dsyn] 0.000623788912876
Beta-Blockers [phsu] 0.000621980463621
setting [ftcn] 0.000621358943779
Method [inpr] 0.000620287528187
mg day [qnco] 0.000619693683952
Dyslipidaemia [dsyn] 0.000618363296376
Ischaemic [ftcn] 0.000614518182917
Wide [spco] 0.000614080454752
deaths [orgf] 0.000613323456639
Reducing [qlco] 0.000610240673284
Normal [qlco] 0.000609698630753
Lung Cancer [neop] 0.000609497975511
Strong [qlco] 0.000609352649085
Leading [tmco] 0.000608679924654
Hospital [hcro, mnob] 0.000608073954808
mg/L [qnco] 0.00060260063802
condition [dsyn] 0.000600972470466
side effects [ftcn] 0.000600108285632
search [inpr] 0.000595915302384
Better [qlco] 0.000595078556711
Occurred [acty] 0.000594015449496
TREAT [ftcn] 0.000593278437042
mice [mamm] 0.000593121591068
Value [qnco] 0.000589316774826
Currently [tmco] 0.000589065062622
Interaction [ftcn] 0.000587560604553
repaglinide [orch, phsu] 0.000585276822384
Progesterone [horm, phsu, strd] 0.00058185102996
Same [qlco] 0.000580099748409
measurements [ftcn] 0.00057976107962
Help [socb] 0.000578759332136
Involved [ftcn] 0.000576128569631
mmol/L [qnco] 0.000575712556964
Relevant [qlco] 0.000574637883949
Defined [cnce] 0.000572352985291
Few [qnco] 0.000572241253639
lack [qlco] 0.000571768431786
Physicians [prog] 0.000570136726887
chronic [tmco] 0.000569441486234
Understanding [menp] 0.000568725098883
Syndromes, Acute Coronary [dsyn] 0.000561046493952
g% [qnco] 0.000558567060441
Alternative [cnce] 0.000556246934539
Recently [tmco] 0.000553618269203
Diseases [dsyn] 0.000553038934931
Types [qlco] 0.000552462925614
Appropriate [qlco] 0.0005468087671
Vascular Malformations [anab] 0.000545845244854
III [inpr] 0.000545360093152
prescribed [hlca] 0.000543479012369
Literature [inpr] 0.000542704323276
Compliance [qnco] 0.000538450095322
Progestins [horm, phsu, strd] 0.000537839715059
Characteristics [qlco] 0.000536622708577
trend [tmco] 0.000536546000607
Discharge [bdsu] 0.00053645989472
Second [qnco] 0.000536027405905
Cost Effectiveness [qnco] 0.000535551939243
Lipids [lipd] 0.000534599492547
Lipid-lowering therapy [topp] 0.000533115841799
???lead [elii, hops] 0.000531878402918
weight [orga] 0.000531486282439
Moderate [qlco] 0.000530989205309
statistically significant [qnco] 0.000530873189909
Measures [qnco] 0.000529796494653
Onset [qlco] 0.000529544996364
Test [lbpr] 0.000529041072396
Estimated [qnco] 0.00052867269712
Modification [ftcn] 0.000527682618739
Low density lipoprotein [aapp, bacs, lipd] 0.000526710322515
Genotype [orga] 0.000526153421728
High density lipoprotein [aapp, bacs, lipd] 0.000525824855263
days [tmco] 0.000525117017403
Lp(a) [aapp, bacs] 0.000524396826779
Hazard Ratio [qnco] 0.000523955648712
General [spco] 0.000519803523625
Bone Mineral Density [clna] 0.000519413544912
procedures [inpr] 0.000518471632516
Six [qnco] 0.000517078406163
DOUBLE BLIND [resa] 0.000516387289856
Associations [menp] 0.00051297706609
Chemoprevention [topp] 0.000512889601307
End [spco] 0.000512681985327
Adult [aggp] 0.000512317782115
strategy [menp] 0.000511315364321
Limited [ftcn] 0.000510377610788
Physical activity [dora] 0.000508247165383
Severity [qlco] 0.000508101713922
Treatments [topp] 0.000506441289919
Novel [tmco] 0.000506122433824
hypertensive [fndg] 0.00050608645294
Goal [inpr] 0.000503983733203
Diagnosed [fndg] 0.000500377069719
Score [qnco] 0.000500375215065
Testosterone [horm, phsu, strd] 0.000499458185458
Ischaemia [dsyn] 0.000496814571122
placebo-controlled [resa] 0.000496722416196
Consecutive [qlco] 0.000496699631043
soy [food] 0.000496509824844
Atherogenesis [patf] 0.000496148311123
Very [qlco] 0.000495206327426
Long [qlco] 0.000494852002219
Science [ocdi] 0.000492466227583
Negative [qlco] 0.000489487658523
tested [inpr] 0.000487829676452
Eight [qnco] 0.00048661683105
Favorable [qlco] 0.000486451985671
topic2
Estrogen [horm, phsu, strd] 0.00481689636838
C-reactive protein [aapp, imft] 0.00346739702534
placebo [topp] 0.00318557708531
N NOS [aapp, imft] 0.00292963545153
randomized [resa] 0.00284881268923
Men [popg] 0.00270898669573
mg% [qnco] 0.00250860053785
Plasma [bdsu] 0.00236265044882
Lipid [lipd] 0.00220475665893
Receive [qlco] 0.00220214257267
Oral [spco] 0.00215639274097
Recent [tmco] 0.002135647924
Myocardial Infarction [dsyn] 0.00200659295221
R- [spco] 0.00197822364979
Stroke [dsyn] 0.00194500706117
Decreased [qnco] 0.00192418535458
Survival [acty] 0.00192382036755
Atherosclerosis [dsyn] 0.00190264469787
Individual [popg] 0.00185200292083
Confidence Interval [qnco] 0.00184648246613
Subject [grup] 0.00183402152085
Measured [qlco] 0.00181783553819
lowering [spco] 0.00181215137778
Diabetes [dsyn] 0.00180861508936
Blood Pressure [orgf] 0.00179844302059
High Risk [qlco] 0.00178923070411
development [phsf] 0.00178408700427
Raloxifene [orch, phsu] 0.00175574268602
Received [qlco] 0.0017440453867
Combined [qlco] 0.00173290725209
vascular [bpoc] 0.00168365781723
Drug [phsu] 0.00167896618358
Non [ftcn] 0.00167821852184
Association [menp] 0.00167708544623
Cases [ftcn] 0.00166733038614
Cholesterol [bacs, strd] 0.00160913326832
Benefit [qnco] 0.00159736763126
Incidence [qnco] 0.00159300920594
Current [tmco] 0.00158878872684
Plus [qlco] 0.00158859090158
Similar [qlco] 0.00153462828629
Therapeutic [topp] 0.00151524182123
Change [ftcn] 0.00150794654743
findings [ftcn] 0.00150520767021
Endothelial [tisu] 0.00150286233077
PREVENT [phsu] 0.00148951123001
Breast Cancer [neop] 0.00148154216017
Assess [acty] 0.00148100967617
Concentrations [menp] 0.00146311596837
Events [evnt] 0.00142942524311
Cancer [neop] 0.00141194863404
Drug Therapy [topp] 0.00141060105543
Progestin [horm, phsu, strd] 0.00140590374465
Evaluated [ftcn] 0.00139318252843
Marker [clna] 0.00138045571983
Response [orga] 0.00137246492736
ischaemic heart disease [dsyn] 0.00136828392637
Available [ftcn] 0.00136491403032
Cardiac [bpoc] 0.00136291978931
Guidelines [inpr] 0.00135174689245
Body Mass Index [diap] 0.00134742934254
Statins [orch, phsu] 0.00134554003824
Death [orgf] 0.00133063815077
Life [idcn] 0.00131985539559
Quality [qlco] 0.00131942489805
Drugs [phsu] 0.00131911668985
Specific [qlco] 0.00130835216283
Total Cholesterol [lbpr] 0.00129751627733
Aged [orga] 0.00129692179392
low [qlco] 0.0012962465605
Elevated [qlco] 0.00128443441856
Following [tmco] 0.00126551092412
weeks [tmco] 0.00125932207411
Dose [qnco] 0.0012583870553
Range [qnco] 0.00125248842058
Equal [qlco] 0.0012500131918
Primary [qlco] 0.00123111506561
function [phsf] 0.00122353259106
Serum [bdsu] 0.00121875461115
Induced [ftcn] 0.001217109235
Users [humn] 0.00121075173472
Acute myocardial infarction [dsyn] 0.00120442453949
Benefits [qnco] 0.00119284508519
coronary artery disease [dsyn] 0.00118577646824
In [qnco] 0.00117294638058
Profile [lbpr] 0.00116992547218
coronary [bpoc] 0.00116896510468
IMPACT [gngm] 0.00115870782038
Administration [ocac] 0.00115850194507
Model [inpr] 0.00114363031907
Young [tmco] 0.00113954057454
WHI [inpr] 0.00113715530289
Assessed [acty] 0.00113572414007
APPEAR [qlco] 0.00113347741881
Percent [qnco] 0.00113211157364
mediated [socb] 0.00112832020192
Improvement [cnce] 0.00112175278486
Cholesterol, LDL [bacs, strd] 0.00111798509452
High Density Lipoprotein Cholesterol [bacs, lipd] 0.00111350020091
Hormone [horm] 0.0011117341084
Well [qlco] 0.00110987734432
Agent [chvf] 0.00110696795855
Early [tmco] 0.00110648506085
Provide [acty] 0.00110415148044
Large [qnco] 0.00110332450462
I- [inch] 0.00108929113212
Heart disease [dsyn] 0.00108761923173
Hormone Therapy [topp] 0.00108696575667
Decrease [qlco] 0.00108519668298
Alone [qnco] 0.00108460547168
Status [qlco] 0.00108442106149
tibolone [phsu, strd] 0.00108108474751
Values [qlco] 0.00107624421621
Prevalence [qnco] 0.00107531097045
C-reactive protein level [lbpr] 0.00106910725284
Examined [fndg] 0.0010674191793
Overall [inpr] 0.00106427439677
Addition [ftcn] 0.00106263868722
Complications [patf] 0.00106203099286
Clinical Trials [resa] 0.00105476364623
Take [hlca] 0.00105410044935
mg dl [qnco] 0.00104813522876
Menopause [phsf] 0.00104479731936
Need [qlco] 0.00104088081308
Several [qnco] 0.00103966295519
Heart failure [dsyn] 0.00103664837296
Presence [topp] 0.0010362492991
Copyright [inpr] 0.00102834011804
median [spco] 0.001024272206
Diagnosis [fndg] 0.0010238368987
Elderly [popg] 0.00102152357976
medroxyprogesterone acetate [horm, phsu, strd] 0.00101720954743
practice [menp] 0.00101550160866
Article [inpr] 0.00101248484559
radiotherapy [inpr] 0.00100982288554
acute [tmco] 0.00100707702438
considered [idcn] 0.00100572682004
Reported [inpr] 0.00100384377406
Likely [qlco] 0.00100013294229
Common [qnco] 0.000986802953098
intervention [hlca] 0.000981280199013
Previous [tmco] 0.000977764624188
homocysteine [aapp, bacs] 0.000975720180726
Four [qnco] 0.000971918299525
Independent [idcn] 0.000969763105009
Combination [qlco] 0.000966704012001
Affect [menp] 0.000965104556568
Possible [qlco] 0.000964889629448
Conduct [inbe] 0.000951326422729
H+ [elii] 0.000950938446225
Purpose [ftcn] 0.000947977850426
LTD [ortf] 0.000946770342795
cardiovascular risk factor [dsyn] 0.000946326274025
Secondary Prevention [topp] 0.000942823520273
Average [qnco] 0.000939865888668
Late [tmco] 0.000928511611686
Old [tmco] 0.000923377627387
symptoms [ftcn] 0.000920676958965
Risks [qlco] 0.000918859602464
participants [popg] 0.000908012295691
Long [qlco] 0.000907993185032
Dependent [qlco] 0.00090412722666
Venous malformation [anab] 0.000900549074414
GIVEN [cnce] 0.000900282428422
Main [qlco] 0.000891869692827
Fasting [fndg] 0.000887089431947
Null [qnco] 0.000884972290251
Cost [qnco] 0.000882906609507
Medical [ftcn] 0.000880936760904
Established [qlco] 0.000879940621895
national [inpr] 0.000879365069907
investigated [ftcn] 0.000878490524893
Compare [acty] 0.000877084419517
Risk factor [qnco] 0.000876853290192
Concentration [menp] 0.000854877488103
Mechanisms [ftcn] 0.000854046184512
Sex [orgf] 0.000854020780943
Part [spco] 0.000847322107727
Published [ocac] 0.000842310400744
Index [inpr] 0.000839778394262
Estradiol [horm, phsu, strd] 0.000838762264033
Type [qlco] 0.000838184671057
Short-term [tmco] 0.000837696852517
Transdermal [ftcn] 0.000836760794831
Approach [spco] 0.000836367879193
Increasing [ftcn] 0.000836014045986
activity [dora] 0.00083310070244
Osteoporosis [dsyn] 0.000829143695996
Reducing [qlco] 0.000827957472487
Smoking [inbe] 0.000824755897897
Strong [qlco] 0.00082184594099
Predictor [idcn] 0.000821045551837
recommendations [idcn] 0.000819182715905
Additional [ftcn] 0.000818424763259
Contribute [acty] 0.000818297363381
Information [idcn] 0.000816441603104
Severe [qlco] 0.000812411157923
objectives [inpr] 0.000805660941131
Parameters [fndg] 0.000805429980907
Aspirin [orch, phsu] 0.000798518598624
Initiative [menp] 0.000797416356539
Estrogens [horm, phsu, strd] 0.000795800774173
diabetic [fndg] 0.000793091825937
progression [patf] 0.000793082083113
Target [ftcn] 0.000788275741348
Future [tmco] 0.000787754733593
Inflammation [patf] 0.000786273948427
Assessment [hlca] 0.000780269938044
experience [menp] 0.00077928701457
Care [acty] 0.000777315661913
hypertensive [fndg] 0.000773888224968
Identified [qlco] 0.000773606923987
Low Density Lipoprotein Cholesterol [bacs, strd] 0.000773476968995
Triglycerides [bacs, lipd] 0.00077075834997
Exercise [dora] 0.000767249040716
Heart [bpoc] 0.000765875153259
Fibrinogen [aapp, bacs, phsu] 0.000765277025987
Diet [food] 0.000763223219448
lack [qlco] 0.000761088343589
Various [irda] 0.000760619104206
Odds Ratio [qnco] 0.000759312904893
Improved [qlco] 0.000758301606736
Dyslipidaemia [dsyn] 0.000757658818529
Adjusted [ftcn] 0.000753702391273
side effects [ftcn] 0.000753683434413
Expression [topp] 0.000747111648819
Multiple [qnco] 0.000746722171215
Endothelium [tisu] 0.000745325987692
Beta-Blockers [phsu] 0.00074514847569
Sample [sbst] 0.000743696355706
premenopausal [tmco] 0.000743263710311
Daily [tmco] 0.000741191973771
Triglyceride [bacs, lipd] 0.000739231098993
Insulin [aapp, horm, phsu] 0.0007381750428
Safety [hcpp] 0.000735187429742
Statin [orch, phsu] 0.000733748950377
Ratio [qnco] 0.000731652047378
Continuous [idcn] 0.000728525884679
Sclerotherapy [topp] 0.000727002419828
Morbidity [qnco] 0.000724944306246
Very [qlco] 0.000721680995236
III [inpr] 0.000720884581912
Issue [fndg] 0.000719532529355
Observational Study [resa] 0.000718826695365
condition [dsyn] 0.000716350081055
Cohort [popg] 0.000708771918561
History [ocdi] 0.000706324158319
Surgery [bmod] 0.000702906291114
Adult [aggp] 0.000701544483462
Make [ftcn] 0.000700738870369
System [ftcn] 0.000698379208563
investigate [ftcn] 0.000697684865928
Few [qnco] 0.000692269627121
Children [aggp] 0.000685854030308
Support [medd] 0.00068551742666
Hospital [hcro, mnob] 0.000685484176584
Evaluation [ftcn] 0.000683878912155
Correlated [qlco] 0.000682786072425
Lipids [lipd] 0.000682166450889
Case [ftcn] 0.000679968099883
Initial [tmco] 0.000678563355663
g% [qnco] 0.000677656603674
Chemoprevention [topp] 0.000676616408214
Inflammatory [ftcn] 0.000674780808899
Diseases [dsyn] 0.000674347832752
strategies [menp] 0.000673742946417
Literature [inpr] 0.000671592367996
Flow [npop] 0.000671307792605
Gender [orga] 0.000668397714136
cardiovascular events [fndg] 0.000666102647858
TREAT [ftcn] 0.000665570023823
Single [popg] 0.00066410994839
Relationship [qlco] 0.000662180965485
Familial hypercholesterolaemia [dsyn] 0.000657376886593
Estrogen Replacement Therapy [topp] 0.000655834489689
HRT [topp] 0.000655669692339
Control Group [grup] 0.000653765882709
Obesity [dsyn] 0.000653758369926
Treatments [topp] 0.000653432800699
Dietary [food] 0.000653319813263
account [idcn] 0.000648023876015
Simvastatin [orch, phsu] 0.000646341637091
Therapies [topp] 0.000644273597798
Recently [tmco] 0.000643923043985
prospective [resa] 0.00064301576969
DOUBLE BLIND [resa] 0.000642823283712
properties [qlco] 0.000641308407364
mice [mamm] 0.000639332143537
Characteristics [qlco] 0.000636225656487
Recommended [idcn] 0.000630754672445
Life Style [socb] 0.000629914373537
Appropriate [qlco] 0.000629601547913
Frequently [tmco] 0.000629105259347
Comparison [acty] 0.000628364624715
mmHg [qnco] 0.000626741001965
Occur [acty] 0.000626571894862
setting [ftcn] 0.000624766055667
Exist [cnce] 0.00062305197527
Relative [famg] 0.000621890604671
Female [fndg] 0.000619640354692
rats [mamm] 0.000616266728988
Measures [qnco] 0.000615373088477
Action [ftcn] 0.00061469121337
Interaction [ftcn] 0.000614250168525
???lead [elii, hops] 0.000612933469993
Cycle [tmco] 0.000608889669233
heart rate [clna] 0.000605396978117
influential [idcn] 0.000605390784436
strategy [menp] 0.000604849731962
Method [inpr] 0.000604307692666
Known [qlco] 0.000601865608016
Event [evnt] 0.000601822769333
Alternative [cnce] 0.000601698772114
Better [qlco] 0.00060003274221
Human [humn] 0.000599090142271
Ischaemic [ftcn] 0.000598299219663
Atherogenesis [patf] 0.000597929424563
Concern [idcn] 0.000596891169011
Involved [ftcn] 0.000594001465301
Relative Risk [qnco] 0.000593702008174
Genotype [orga] 0.000592579561582
Needed [qlco] 0.00059192324201
Lipoproteins [aapp, bacs] 0.00059154560772
Start [tmco] 0.00059063513418
Authors [prog] 0.000589520290478
Hypothesis [idcn] 0.000588888404971
Chemotherapy [topp] 0.00058555753097
Often [tmco] 0.000584888694509
soy [food] 0.000584085920666
mg/L [qnco] 0.000583901204347
Inhibition [menp] 0.000578356726301
regimens [inpr] 0.000573606743222
confirmed [qlco] 0.000571144212103
Replacement [topp] 0.00057088716287
Primary Prevention [topp] 0.000569753103329
Occurred [acty] 0.000569424388726
Moderate [qlco] 0.000568935311992
Education [edac] 0.000567715129253
Same [qlco] 0.00056711623676
Help [socb] 0.000564060932835
Prognostic Factor [clna] 0.000563045363777
Indicated [fndg] 0.000557790800227
measurements [ftcn] 0.00055716072672
Limited [ftcn] 0.000556168338372
Favorable [qlco] 0.000553954315032
Equine [mamm] 0.000552941137447
Question [inpr] 0.000551343167978
Goal [inpr] 0.000551077369408
variables [qlco] 0.000549265843743
Five [qnco] 0.000548990822367
Value [qnco] 0.000548812035757
Atrial Fibrillation [patf] 0.000547176361403
Lipid-lowering therapy [topp] 0.000541264944475
Expected [idcn] 0.000538888695089
People [popg] 0.000537875596281
Modified [ftcn] 0.000536682267032
Lp(a) [aapp, bacs] 0.000534721632364
chronic [tmco] 0.000533627399136
Low dose [qnco] 0.000532538806342
repaglinide [orch, phsu] 0.000532470529985
Ireland [geoa] 0.00053224010295
Relevant [qlco] 0.00053167540073
Chronic heart failure [dsyn] 0.000526960251012
Select [acty] 0.000526557264449
MODIFY [ftcn] 0.000525919514885
Arterial [bpoc] 0.000524116213536
Novel [tmco] 0.000524064880752
Mechanism [ftcn] 0.000523415025643
Phytoestrogens [horm, phsu, strd] 0.000522255301204
End Point [qlco] 0.000520582167071
Decade [qnco] 0.000519448441715
Past [tmco] 0.000519083936498
prescribed [hlca] 0.000517981881111
Conjugated estrogen [horm, phsu, strd] 0.000516050374002
High density lipoprotein [aapp, bacs, lipd] 0.000515669193781
Third [qnco] 0.000514475029187
Measure [qnco] 0.000514280119391
Then [tmco] 0.000512924382249
Program [cnce] 0.00050928960407
Doses [qnco] 0.000506952407242
Test [lbpr] 0.000504835296858
Hazard Ratio [qnco] 0.000503933569235
Determinant [ftcn] 0.000502917568491
secondary [neop] 0.000502334646563
Poor [grpa] 0.000501388809128
rosuvastatin [orch, phsu] 0.000501135211761
statistically significant [qnco] 0.000501050471531
Little NOS [cgab, dsyn] 0.00050050211957
Bone Mineral Density [clna] 0.000499532425658
month [tmco] 0.000499408372014
Protection [fndg] 0.000498033334073
Negative [qlco] 0.000497562085188
Knowledge [inpr] 0.000497126836547
Cost Effectiveness [qnco] 0.000495240020586
plasma concentration [qnco] 0.000494539953376
Point [qnco] 0.000494099944091
Glucose [bacs, carb, phsu] 0.000493641200924
Controlled [ftcn] 0.000493247796356
If [qlco] 0.000492537388114
Blood [tisu] 0.000492454156293
topic3
Estrogen [horm, phsu, strd] 0.00555292684014
N NOS [aapp, imft] 0.00351757015421
placebo [topp] 0.00300023559765
C-reactive protein [aapp, imft] 0.00281187889443
randomized [resa] 0.00269871555834
Men [popg] 0.00259256654247
Oral [spco] 0.00247914869236
mg% [qnco] 0.00232058548468
Current [tmco] 0.00226284224959
Myocardial Infarction [dsyn] 0.00223260933382
Blood Pressure [orgf] 0.00220472294637
findings [ftcn] 0.0020889193517
coronary [bpoc] 0.00206463764522
Measured [qlco] 0.00204886101973
Stroke [dsyn] 0.0019693289381
Plasma [bdsu] 0.00195111630629
Breast Cancer [neop] 0.00193597658995
Similar [qlco] 0.00192284402527
Death [orgf] 0.00183771155204
development [phsf] 0.00183103787928
Subject [grup] 0.00182114057518
Combined [qlco] 0.00180451827299
Raloxifene [orch, phsu] 0.00177591722187
Cholesterol [bacs, strd] 0.00176775774857
Individual [popg] 0.00176280160357
Diabetes [dsyn] 0.00175115434181
Recent [tmco] 0.00174657087486
Decrease [qlco] 0.00174329345922
Statins [orch, phsu] 0.00173597917781
Drug Therapy [topp] 0.00172693441341
Menopause [phsf] 0.00171863656112
Lipid [lipd] 0.00170682049645
Atherosclerosis [dsyn] 0.00168796312155
Administration [ocac] 0.00168239816405
lowering [spco] 0.00162261522022
Acute myocardial infarction [dsyn] 0.00160563459765
IMPACT [gngm] 0.00160165251151
Plus [qlco] 0.00158947413816
R- [spco] 0.00158172494661
Receive [qlco] 0.00157421942072
Change [ftcn] 0.0015726046013
WHI [inpr] 0.00156965058857
Cancer [neop] 0.00156544953041
Non [ftcn] 0.00155218633481
Cardiac [bpoc] 0.00155040549866
Early [tmco] 0.00154754798721
Association [menp] 0.00151782747038
Confidence Interval [qnco] 0.00151623875897
Old [tmco] 0.00150505648809
Large [qnco] 0.00150426269594
Benefit [qnco] 0.00148169086885
function [phsf] 0.00145723145141
Dose [qnco] 0.00144459550622
Concentrations [menp] 0.00143501832635
Profile [lbpr] 0.00143350969557
Decreased [qnco] 0.00142833283526
Evaluated [ftcn] 0.00142428932714
Need [qlco] 0.00141696410937
Incidence [qnco] 0.00140171740092
weeks [tmco] 0.00138078828958
vascular [bpoc] 0.00137790413818
intervention [hlca] 0.00137621478513
Values [qlco] 0.0013700170069
Several [qnco] 0.00134869580166
Received [qlco] 0.00134422352631
Events [evnt] 0.00133846099861
Young [tmco] 0.00133719217165
Future [tmco] 0.00132274275339
Drugs [phsu] 0.00131767632092
Well [qlco] 0.00131763027337
Prevalence [qnco] 0.00130660212944
Aged [orga] 0.0013006500363
Endothelial [tisu] 0.00130055866791
Smoking [inbe] 0.00129017666644
PREVENT [phsu] 0.00128747881581
Target [ftcn] 0.00128394432279
Medical [ftcn] 0.0012780828761
Equal [qlco] 0.00127749437834
Common [qnco] 0.00126743258156
Odds Ratio [qnco] 0.00125768633697
Range [qnco] 0.00125394175695
Users [humn] 0.00124848704368
Assess [acty] 0.00124721807423
Life [idcn] 0.00122706121304
Therapeutic [topp] 0.00122564671395
Predictor [idcn] 0.00122325210421
Induced [ftcn] 0.0012159514738
Likely [qlco] 0.0012073589136
Inflammation [patf] 0.00120073892077
median [spco] 0.00119734020813
APPEAR [qlco] 0.00119410072634
Model [inpr] 0.00119368564625
Quality [qlco] 0.0011896462995
Specific [qlco] 0.00118801632109
Progestin [horm, phsu, strd] 0.00118713527534
Elderly [popg] 0.0011811318844
Main [qlco] 0.00116154311114
Heart failure [dsyn] 0.00115124461221
low [qlco] 0.00114771120891
Published [ocac] 0.00114547797213
Marker [clna] 0.00114295856323
Response [orga] 0.00113439254748
Complications [patf] 0.00113233975844
History [ocdi] 0.00112492494479
symptoms [ftcn] 0.00111246848514
Sex [orgf] 0.00111041697471
High Risk [qlco] 0.00110726952725
Total Cholesterol [lbpr] 0.00110665338521
Parameters [fndg] 0.00109789845838
participants [popg] 0.00108616903957
Transdermal [ftcn] 0.00108299519424
Statin [orch, phsu] 0.00108282239131
Improvement [cnce] 0.00107858276526
Dyslipidaemia [dsyn] 0.00106985858935
Triglycerides [bacs, lipd] 0.00106940424239
mediated [socb] 0.00105252958971
Osteoporosis [dsyn] 0.00105160971815
Cases [ftcn] 0.00104713384281
Estrogens [horm, phsu, strd] 0.00104683012962
radiotherapy [inpr] 0.00104589338199
Estradiol [horm, phsu, strd] 0.00104354801599
tibolone [phsu, strd] 0.00103371895272
Take [hlca] 0.00102982563045
Following [tmco] 0.00102736466145
Morbidity [qnco] 0.00102688857562
Equine [mamm] 0.00102523230137
Risk factor [qnco] 0.00102206753688
Possible [qlco] 0.00102154109852
Approach [spco] 0.00101892936934
Make [ftcn] 0.0010116544641
Dietary [food] 0.00100995232886
Assessed [acty] 0.00100964268004
Body Mass Index [diap] 0.00100652364691
Reported [inpr] 0.00100592045655
Type [qlco] 0.00100460569663
Purpose [ftcn] 0.000997897328277
Survival [acty] 0.000995508614253
LTD [ortf] 0.000993865216406
I- [inch] 0.000992742391776
Clinical Trials [resa] 0.000987573544266
setting [ftcn] 0.000986809942023
Initiative [menp] 0.000986560891312
Heart disease [dsyn] 0.000980752648971
ischaemic heart disease [dsyn] 0.000972367642769
coronary artery disease [dsyn] 0.000971980268791
Concentration [menp] 0.000971883567648
Benefits [qnco] 0.000969305964118
Combination [qlco] 0.000967866886844
Serum [bdsu] 0.000965558675906
Provide [acty] 0.00096472259292
Index [inpr] 0.000958788915951
Null [qnco] 0.000956093787099
Care [acty] 0.000953178454873
Duration [tmco] 0.000952933435282
Known [qlco] 0.000952160971581
mg dl [qnco] 0.000946289279705
practice [menp] 0.000945576176826
Identified [qlco] 0.000944265702757
Affect [menp] 0.000942032115266
Increasing [ftcn] 0.000938662608278
activity [dora] 0.000938352636105
Alone [qnco] 0.000937835563918
Article [inpr] 0.000935316272919
Copyright [inpr] 0.000927623001385
Risks [qlco] 0.000926324585112
Conduct [inbe] 0.000913021488994
Venous malformation [anab] 0.000911487996298
Agent [chvf] 0.000910152833063
Percent [qnco] 0.000909813302419
Overall [inpr] 0.000904841817534
Drug [phsu] 0.000899080193601
Support [medd] 0.000895766373265
Long [qlco] 0.000894214059487
Independent [idcn] 0.000893403553561
Diagnosis [fndg] 0.000890319046065
Relative [famg] 0.000878038161003
cardiovascular events [fndg] 0.000877388226967
Fasting [fndg] 0.000875597593243
Daily [tmco] 0.000874678164944
Hormone Therapy [topp] 0.00087033234761
homocysteine [aapp, bacs] 0.000855292168377
High Density Lipoprotein Cholesterol [bacs, lipd] 0.000854268017688
Status [qlco] 0.000854221159662
C-reactive protein level [lbpr] 0.000852854304787
Endothelium [tisu] 0.000846345459647
In [qnco] 0.000845202467963
Action [ftcn] 0.000841298124662
Mechanisms [ftcn] 0.000837142430967
Heart [bpoc] 0.000836512335922
Reducing [qlco] 0.000836123715657
Previous [tmco] 0.000834019826912
Cholesterol, LDL [bacs, strd] 0.000829854917107
Conjugated estrogen [horm, phsu, strd] 0.000827291450448
Information [idcn] 0.000824476614277
medroxyprogesterone acetate [horm, phsu, strd] 0.000821685433754
Addition [ftcn] 0.000819106702274
rats [mamm] 0.000818657932489
Established [qlco] 0.000818602942614
Guidelines [inpr] 0.000816800530531
H+ [elii] 0.000814811516047
Compare [acty] 0.00080622087095
Safety [hcpp] 0.000803061628914
cardiovascular risk factor [dsyn] 0.00080144534915
investigated [ftcn] 0.000796902044377
Needed [qlco] 0.000793230303637
Progesterone [horm, phsu, strd] 0.000786978516403
acute [tmco] 0.000786718033969
Various [irda] 0.000784687121203
Recently [tmco] 0.000784074059696
III [inpr] 0.000782463658661
Presence [topp] 0.000778923728724
HRT [topp] 0.000778755541721
considered [idcn] 0.000773151203181
Sample [sbst] 0.000772468778374
Four [qnco] 0.000770360667385
Examined [fndg] 0.000770199600084
Flow [npop] 0.000769875764343
heart rate [clna] 0.000767447068554
Estrogen Replacement Therapy [topp] 0.000766797543271
variables [qlco] 0.000761542303261
Exercise [dora] 0.000755216819717
Secondary Prevention [topp] 0.000746018001724
g% [qnco] 0.000733774132185
Adjusted [ftcn] 0.000732547319368
Elevated [qlco] 0.000730865460777
Additional [ftcn] 0.00072569691494
Short-term [tmco] 0.000714363168963
Atrial Fibrillation [patf] 0.000712948839085
objectives [inpr] 0.00071286078508
Available [ftcn] 0.00071226087172
influential [idcn] 0.000708812239251
Surgery [bmod] 0.000708047328768
Strong [qlco] 0.000707460823552
Evaluation [ftcn] 0.000706920218532
experience [menp] 0.000706891160773
Cost [qnco] 0.000706498398776
Dependent [qlco] 0.000704946827278
Part [spco] 0.000704774262419
Insulin [aapp, horm, phsu] 0.000704600397976
Blood [tisu] 0.000704578497961
Improved [qlco] 0.000699560178368
properties [qlco] 0.000698256440381
Menopausal [phsf] 0.000695916584556
Primary [qlco] 0.00069416653979
Observational Study [resa] 0.000692138199155
???lead [elii, hops] 0.000691428234603
Literature [inpr] 0.000689369545582
Aspirin [orch, phsu] 0.000687168237447
Severe [qlco] 0.000684835680679
Occur [acty] 0.000682100580475
Concern [idcn] 0.000679300735557
General [spco] 0.000675792698238
Continuous [idcn] 0.000675257169524
Goal [inpr] 0.000675226649791
rosuvastatin [orch, phsu] 0.000674892060082
Relationship [qlco] 0.000673791145918
Required [ftcn] 0.000669471641121
premenopausal [tmco] 0.000668939397807
Characteristics [qlco] 0.000667680974914
strategies [menp] 0.000664646363571
Frequently [tmco] 0.000663965833329
Limited [ftcn] 0.000661497196768
month [tmco] 0.00066113754336
Atherogenesis [patf] 0.000652507243018
Average [qnco] 0.000646658932543
recommendations [idcn] 0.000643557425917
Simvastatin [orch, phsu] 0.000639943471054
System [ftcn] 0.000635980849063
regimens [inpr] 0.00063362178555
End Point [qlco] 0.000633503183826
Obtained [ftcn] 0.000633163006226
Recommended [idcn] 0.000631437748606
Associations [menp] 0.000631055223088
Hospital [hcro, mnob] 0.00062939224275
Comparison [acty] 0.000629160710362
Low Density Lipoprotein Cholesterol [bacs, strd] 0.000626475016819
Case [ftcn] 0.000625260529432
Hypothesis [idcn] 0.0006234892881
Better [qlco] 0.000620141893574
Diet [food] 0.000616666897447
national [inpr] 0.000613318948845
Assessment [hlca] 0.000612965778485
Issue [fndg] 0.000612007605747
Doses [qnco] 0.000611788650902
Physical activity [dora] 0.000611684904712
Familial hypercholesterolaemia [dsyn] 0.000611671585196
Control Group [grup] 0.000611448171377
Diseases [dsyn] 0.000611070611237
Contribute [acty] 0.000606317667934
MODIFY [ftcn] 0.000604938405921
prescribed [hlca] 0.000604523035662
Genotype [orga] 0.000602570761501
Triglyceride [bacs, lipd] 0.000602554178609
Relative Risk [qnco] 0.000601355891539
mmol/L [qnco] 0.000600983656962
DOUBLE BLIND [resa] 0.000600890681249
Often [tmco] 0.000599887718814
mice [mamm] 0.000599237782328
Single [popg] 0.000597353619361
secondary [neop] 0.000597295157668
Age-Years [tmco] 0.000596922863801
GIVEN [cnce] 0.0005955618419
repaglinide [orch, phsu] 0.000592793715462
confirmed [qlco] 0.000592311010848
investigate [ftcn] 0.000591828068711
Area [geoa] 0.000590104445867
Appropriate [qlco] 0.000588497641683
Therapies [topp] 0.000588367473391
side effects [ftcn] 0.000587552999671
Medications [phsu] 0.000586121874465
Expected [idcn] 0.000584039180767
Inflammatory [ftcn] 0.00058376575057
Variability [cnce] 0.000583094727465
Measure [qnco] 0.000582161075932
Occurred [acty] 0.000581980194197
Normal [qlco] 0.000580374564176
Science [ocdi] 0.000578816291867
Moderate [qlco] 0.000577161172997
progression [patf] 0.000576537789593
Score [qnco] 0.000575017768254
Prognostic Factor [clna] 0.000573495383083
Currently [tmco] 0.000573435293218
Hormone [horm] 0.000571620679999
Good [qlco] 0.000571101307861
GY [geoa] 0.000569839802148
Lung Cancer [neop] 0.000568794096416
Small [qnco] 0.000567309091469
Initial [tmco] 0.00056600248464
Alternative [cnce] 0.000564338966898
reductions [npop] 0.00056417097239
Adult [aggp] 0.000558662359469
prospective [resa] 0.000557946359419
Ratio [qnco] 0.000557487775043
Five [qnco] 0.000555667398251
mmHg [qnco] 0.000554189585451
Fibrinogen [aapp, bacs, phsu] 0.000553845205517
Lipoproteins [aapp, bacs] 0.000552994250374
mg day [qnco] 0.000552860005729
Multiple [qnco] 0.000552657519167
Chemoprevention [topp] 0.000551727388281
Ireland [geoa] 0.000547682083496
Point [qnco] 0.000547583120891
Low dose [qnco] 0.000546616836913
Attention [menp] 0.000545876483551
Cost Effectiveness [qnco] 0.00054513010869
Treatments [topp] 0.000543379019297
End [spco] 0.000543216368344
Interaction [ftcn] 0.000542662419506
soy [food] 0.000541145075604
diabetic [fndg] 0.000540904836396
Screening [hlca] 0.000540896371668
Cardiovascular Diseases [dsyn] 0.000539486147145
Prognosis [hlca] 0.000538231351132
Physicians [prog] 0.000537133887313
Hazard Ratio [qnco] 0.000536827548266
Mechanism [ftcn] 0.000535803625795
mg/L [qnco] 0.000535213273459
Beta-Blockers [phsu] 0.000535173413106
patient care [hlca] 0.000534424381683
Adjustment [inbe] 0.00053375280708
Obesity [dsyn] 0.000533712225845
plasma concentration [qnco] 0.000532314339941
lack [qlco] 0.0005308295266
Children [aggp] 0.000530483109545
Direct [qlco] 0.000530127763155
Program [cnce] 0.000530107509011
Favorable [qlco] 0.000528803350485
Consecutive [qlco] 0.000528517474016
Chemotherapy [topp] 0.000526404277924
condition [dsyn] 0.000525251750411
Negative [qlco] 0.000524498690184
matched [resa] 0.000524344857298
Dilation [patf] 0.000522163456657
Female [fndg] 0.00052074484163
strategy [menp] 0.000520446550371
Cl - [elii] 0.000518635797889
Event [evnt] 0.000517371144329
Administered [ftcn] 0.000514865052746
Basis [ftcn] 0.000514555029153
Leading [tmco] 0.00051401266924
adverse events [fndg] 0.000511975211914
Six [qnco] 0.000511359011596
Sclerotherapy [topp] 0.000510017171336
Hypercholesterolaemia [dsyn] 0.000507065390564
MEDLINE [inpr] 0.00050568375678
Bone Mineral Density [clna] 0.000504591716042
Decade [qnco] 0.00050429643082
Course [tmco] 0.000504211058132
Now [tmco] 0.000502606162002
Method [inpr] 0.000502547248574
Beta [plnt] 0.000501256442445
Select [acty] 0.000501005547515
Cohort [popg] 0.000500947544482
Estimated [qnco] 0.000499351695538
hypertensive [fndg] 0.000499235919604
Low density lipoprotein [aapp, bacs, lipd] 0.000497991584498
Past [tmco] 0.000497883126544
Angina, Unstable [dsyn] 0.000496446824812
Seen [qlco] 0.000495824175093
search [inpr] 0.00049511217042
topic4
Estrogen [horm, phsu, strd] 0.00411079348556
N NOS [aapp, imft] 0.00404492121531
placebo [topp] 0.00318079419459
C-reactive protein [aapp, imft] 0.00317796664274
Stroke [dsyn] 0.0029851571041
Blood Pressure [orgf] 0.00283016729339
Subject [grup] 0.00252646230267
Oral [spco] 0.00236353944812
Men [popg] 0.00222168545843
mg% [qnco] 0.00221900972095
Decreased [qnco] 0.00220924265652
function [phsf] 0.00209336044539
Death [orgf] 0.00209196876409
Raloxifene [orch, phsu] 0.00208146700445
R- [spco] 0.00207025009285
Confidence Interval [qnco] 0.00202487107068
Recent [tmco] 0.00196003411348
Individual [popg] 0.00192732392242
Benefit [qnco] 0.0019098438112
Current [tmco] 0.00185056606657
Early [tmco] 0.00182526941368
Non [ftcn] 0.00180325480088
Old [tmco] 0.00179861620427
Measured [qlco] 0.00174909922933
Received [qlco] 0.00173926781819
vascular [bpoc] 0.001738812621
High Risk [qlco] 0.00172555546938
findings [ftcn] 0.00171340940564
radiotherapy [inpr] 0.00169496227179
Cases [ftcn] 0.00167697017926
Similar [qlco] 0.00166339484004
randomized [resa] 0.00165302880692
Several [qnco] 0.00165051396096
Association [menp] 0.00164770270995
Available [ftcn] 0.00161870569044
Statins [orch, phsu] 0.00160955941897
Combined [qlco] 0.0016072673379
Atherosclerosis [dsyn] 0.00157591199696
Breast Cancer [neop] 0.00156237267301
Drug [phsu] 0.00155035217378
Aged [orga] 0.00154620652136
Plus [qlco] 0.00154345831875
Evaluated [ftcn] 0.00153936070232
PREVENT [phsu] 0.00153559654542
Total Cholesterol [lbpr] 0.00150572153296
Large [qnco] 0.00148605891211
Incidence [qnco] 0.00148012585949
Drugs [phsu] 0.00147814285406
Elevated [qlco] 0.00146406105683
Diabetes [dsyn] 0.00145411425356
Change [ftcn] 0.0014464968256
Receive [qlco] 0.00144631577356
coronary [bpoc] 0.00143490567092
Independent [idcn] 0.0014321327285
Reported [inpr] 0.00142793700633
Plasma [bdsu] 0.00142627301726
Decrease [qlco] 0.00142237525184
Endothelial [tisu] 0.00139245718348
Specific [qlco] 0.00138951019467
Myocardial Infarction [dsyn] 0.00137646089518
development [phsf] 0.00137227656122
Prevalence [qnco] 0.00136965494028
Life [idcn] 0.00134402045307
Quality [qlco] 0.00134188665573
Response [orga] 0.00133496636998
Drug Therapy [topp] 0.00132914761164
Affect [menp] 0.00131458442521
Induced [ftcn] 0.00131431629297
tibolone [phsu, strd] 0.00129969025821
Administration [ocac] 0.0012971501046
Well [qlco] 0.00129292160193
Events [evnt] 0.00128282788549
Odds Ratio [qnco] 0.00128159389329
Cardiac [bpoc] 0.00127659707312
Therapeutic [topp] 0.00127516554042
Model [inpr] 0.00126410690928
Body Mass Index [diap] 0.0012594900566
Likely [qlco] 0.00125536121416
intervention [hlca] 0.00124766480388
weeks [tmco] 0.0012421932048
Guidelines [inpr] 0.00121976846906
Purpose [ftcn] 0.00121155033657
Osteoporosis [dsyn] 0.00120908688566
Benefits [qnco] 0.00120782415404
Lipid [lipd] 0.00120670688637
Equal [qlco] 0.00119904461447
Flow [npop] 0.0011927951433
Statin [orch, phsu] 0.0011911559895
coronary artery disease [dsyn] 0.00119013032613
Assessed [acty] 0.00118459386829
Cancer [neop] 0.00118421598785
Provide [acty] 0.00118269631147
Acute myocardial infarction [dsyn] 0.00118011088386
Dose [qnco] 0.00117902678975
Cholesterol [bacs, strd] 0.00117599145618
APPEAR [qlco] 0.00116695889022
Mechanisms [ftcn] 0.001165213978
Article [inpr] 0.00116357694662
acute [tmco] 0.00116189318021
Alone [qnco] 0.00116186494318
I- [inch] 0.00115639619672
Approach [spco] 0.00115393183242
Smoking [inbe] 0.00114535655032
Take [hlca] 0.00114071766464
Information [idcn] 0.00113587853441
Make [ftcn] 0.00113449509178
mediated [socb] 0.00113421479791
Menopause [phsf] 0.00112644727908
mg dl [qnco] 0.00112207462435
Primary [qlco] 0.00112011377201
High Density Lipoprotein Cholesterol [bacs, lipd] 0.00111609129938
Profile [lbpr] 0.00111477114136
Complications [patf] 0.00111108671214
Need [qlco] 0.00109334647488
Range [qnco] 0.00108712718607
Additional [ftcn] 0.00108347428384
LTD [ortf] 0.00107550445723
Values [qlco] 0.00107223106253
Following [tmco] 0.00107014167669
Estradiol [horm, phsu, strd] 0.00106840821636
Conduct [inbe] 0.00106684619371
ischaemic heart disease [dsyn] 0.00106444215982
Progestin [horm, phsu, strd] 0.00104889708995
Improvement [cnce] 0.0010433443418
History [ocdi] 0.00103819099764
IMPACT [gngm] 0.00103421181832
Addition [ftcn] 0.00102980753831
setting [ftcn] 0.00102812018372
Clinical Trials [resa] 0.0010238855431
Possible [qlco] 0.00102115583546
WHI [inpr] 0.00101416432236
Hormone Therapy [topp] 0.00101292756263
Common [qnco] 0.00101141168751
cardiovascular risk factor [dsyn] 0.00101105992159
Index [inpr] 0.00100322334364
Assess [acty] 0.00100194162407
Four [qnco] 0.000999486514595
Predictor [idcn] 0.000997361869397
Fasting [fndg] 0.000993194779963
lowering [spco] 0.00099225347715
Null [qnco] 0.000991266143941
Target [ftcn] 0.000985686541812
low [qlco] 0.000982379638387
Users [humn] 0.000978422730945
Agent [chvf] 0.000976137381303
Initiative [menp] 0.000975761501817
Combination [qlco] 0.000974164522747
Marker [clna] 0.000972872319049
Concentrations [menp] 0.000971053209784
Overall [inpr] 0.000967645310994
homocysteine [aapp, bacs] 0.000963391460994
Young [tmco] 0.000958592669066
Elderly [popg] 0.000955975856617
Serum [bdsu] 0.000952968353263
Status [qlco] 0.000949820548258
Survival [acty] 0.000940171277411
symptoms [ftcn] 0.000937888243456
cardiovascular events [fndg] 0.000928601545536
Cholesterol, LDL [bacs, strd] 0.00090501010806
Average [qnco] 0.000893528125525
Heart disease [dsyn] 0.000877909151844
experience [menp] 0.000875125923644
Copyright [inpr] 0.000866543429252
heart rate [clna] 0.000866127795963
Daily [tmco] 0.000862352533873
Needed [qlco] 0.000861764304718
Presence [topp] 0.000861411671625
rats [mamm] 0.000857630700809
GIVEN [cnce] 0.000855641423334
Duration [tmco] 0.000855220112614
Identified [qlco] 0.000849260394661
Dyslipidaemia [dsyn] 0.000848746876968
Type [qlco] 0.00084529587023
median [spco] 0.000837706563807
Triglycerides [bacs, lipd] 0.000836565334669
investigated [ftcn] 0.000832506370474
considered [idcn] 0.00083193229224
Sex [orgf] 0.00083012046774
Support [medd] 0.000829272413149
condition [dsyn] 0.000827395997103
Established [qlco] 0.000826945996143
Recommended [idcn] 0.00082604636867
Known [qlco] 0.000824146647594
Same [qlco] 0.000822030531851
Dependent [qlco] 0.000821737764864
Morbidity [qnco] 0.000819386029905
Heart [bpoc] 0.00081879427088
Examined [fndg] 0.000815276538082
activity [dora] 0.000812194566339
Safety [hcpp] 0.000811806276134
Dietary [food] 0.000810219321744
H+ [elii] 0.000809338958199
Estrogens [horm, phsu, strd] 0.000808117779006
Life Style [socb] 0.000807221977142
Increasing [ftcn] 0.000803379719157
Various [irda] 0.000799522873491
Hormone [horm] 0.000798759961643
Action [ftcn] 0.000797791216218
Concentration [menp] 0.000797469364771
soy [food] 0.000791381229678
Compare [acty] 0.000787933948514
Endothelium [tisu] 0.000785137137745
Physicians [prog] 0.000780895180071
prospective [resa] 0.000780444627225
Long [qlco] 0.000780028481208
Previous [tmco] 0.000777403831812
Aspirin [orch, phsu] 0.000776718369699
Part [spco] 0.000776506022187
month [tmco] 0.00077434033478
Severe [qlco] 0.000773094751102
Contribute [acty] 0.000772156487824
investigate [ftcn] 0.000769229331404
strategies [menp] 0.000765488322065
Variability [cnce] 0.000763635003478
Low Density Lipoprotein Cholesterol [bacs, strd] 0.0007595118918
Cohort [popg] 0.000758910483641
Short-term [tmco] 0.000758774594968
Continuous [idcn] 0.000754561758489
Main [qlco] 0.000753381319579
In [qnco] 0.000751658799645
Diagnosis [fndg] 0.000750594019147
MODIFY [ftcn] 0.000749711178749
Medical [ftcn] 0.000744039152154
hypertensive [fndg] 0.000743805773839
Event [evnt] 0.000741574489979
Care [acty] 0.000741173630576
Future [tmco] 0.000740459630064
Literature [inpr] 0.000734564779707
Inflammation [patf] 0.000730809333225
Issue [fndg] 0.000730562203926
Sclerotherapy [topp] 0.00072757164393
Reducing [qlco] 0.000727531399635
Assessment [hlca] 0.000725029172404
Percent [qnco] 0.000724974476808
Improved [qlco] 0.000721969068524
Transdermal [ftcn] 0.000721637877159
Female [fndg] 0.000720699912394
Single [popg] 0.000720257892246
Relative Risk [qnco] 0.000717611330048
Adjusted [ftcn] 0.000716229625996
g% [qnco] 0.000715036220548
Interaction [ftcn] 0.000714792408262
Control Group [grup] 0.000708972259936
Associations [menp] 0.000702528286962
objectives [inpr] 0.000701387982416
Low density lipoprotein [aapp, bacs, lipd] 0.000700920757628
Published [ocac] 0.000699819010358
Multiple [qnco] 0.000699489414764
Evaluation [ftcn] 0.000699317292249
Seen [qlco] 0.000697389795851
Better [qlco] 0.000696500672409
Equine [mamm] 0.000695430226073
Relative [famg] 0.000693686387287
medroxyprogesterone acetate [horm, phsu, strd] 0.000691311173149
Select [acty] 0.000689965569424
premenopausal [tmco] 0.000687479188002
Estrogen Replacement Therapy [topp] 0.000684451797019
participants [popg] 0.000683803157319
Risk factor [qnco] 0.000681553279668
Measure [qnco] 0.000681125294436
Surgery [bmod] 0.00067996687731
search [inpr] 0.000679873360007
Relationship [qlco] 0.000678162061525
Parameters [fndg] 0.000668799154483
Small [qnco] 0.000668408397094
Method [inpr] 0.000666532047858
Observational Study [resa] 0.000664577926778
Conjugated estrogen [horm, phsu, strd] 0.000663994253354
Late [tmco] 0.000658734242393
recommendations [idcn] 0.000652495583318
Fibrinogen [aapp, bacs, phsu] 0.000649477794808
Ireland [geoa] 0.000649041061333
Limited [ftcn] 0.000648466064401
Case [ftcn] 0.000647860000007
Heart failure [dsyn] 0.000646056035142
confirmed [qlco] 0.000642500073179
C-reactive protein level [lbpr] 0.000639473515816
Treatments [topp] 0.000639377579635
side effects [ftcn] 0.000638320093496
Test [lbpr] 0.000635755006364
Insulin [aapp, horm, phsu] 0.000632945123431
Negative [qlco] 0.000631922725472
Risks [qlco] 0.000629688022041
Syndromes, Acute Coronary [dsyn] 0.000629229130453
Doses [qnco] 0.000629168221486
Poor [grpa] 0.000627306304525
Cost [qnco] 0.000626487460027
Five [qnco] 0.000626245704533
Point [qnco] 0.000625901604309
Obesity [dsyn] 0.000625729749912
Revealed [qlco] 0.000625664968535
Characteristics [qlco] 0.000624568657915
Triglyceride [bacs, lipd] 0.000623959586559
Hazard Ratio [qnco] 0.000620909886748
Strong [qlco] 0.000619270576777
practice [menp] 0.000617764669836
Ischaemic [ftcn] 0.000617321515518
Inflammatory [ftcn] 0.000617049933707
Lung Cancer [neop] 0.000615948574809
adverse events [fndg] 0.000613433399934
Low dose [qnco] 0.000611727839946
statistically significant [qnco] 0.000610795343127
Venous malformation [anab] 0.000605154989786
Cycle [tmco] 0.000604665746265
Lipoproteins [aapp, bacs] 0.000604524206097
choice [inbe] 0.000603263860882
variables [qlco] 0.000603059669388
???lead [elii, hops] 0.000600458051387
Recently [tmco] 0.000599181776973
Gender [orga] 0.000598807243303
mg day [qnco] 0.000598234183618
Medications [phsu] 0.000597280041062
prescribed [hlca] 0.000597036661216
Regimen [topp] 0.000595593529388
Six [qnco] 0.000595138445545
mmHg [qnco] 0.000594184396687
Ratio [qnco] 0.000593685843567
High density lipoprotein [aapp, bacs, lipd] 0.000592306052561
Very [qlco] 0.000591619760209
Defined [cnce] 0.000591070199296
lack [qlco] 0.000590185659585
Contrast [qlco] 0.00058971069122
Human [humn] 0.000587447354635
influential [idcn] 0.000587213410956
Currently [tmco] 0.00058696073077
Exercise [dora] 0.000584826860512
Understanding [menp] 0.000584584504028
Hospital [hcro, mnob] 0.000583554905306
System [ftcn] 0.000582526908914
regimens [inpr] 0.000581639801809
HRT [topp] 0.000581150541416
mmol/L [qnco] 0.000579905662113
national [inpr] 0.00057848380622
Score [qnco] 0.000574509632868
Adhesion Molecule [aapp, bacs] 0.000573784614067
Atherogenesis [patf] 0.000573363562834
Hypercholesterolaemia [dsyn] 0.000573195693681
Third [qnco] 0.000572491560348
atorvastatin [orch, phsu] 0.000572454183043
III [inpr] 0.000572194540356
reductions [npop] 0.000570742835107
Secondary Prevention [topp] 0.000570685944191
Direct [qlco] 0.000568883498992
Adult [aggp] 0.000567331645499
Replacement [topp] 0.000564727653456
mg/L [qnco] 0.000563269304458
Chemoprevention [topp] 0.0005632626958
Now [tmco] 0.000559950871565
Activation [acty] 0.000558168436799
chronic [tmco] 0.00055736097653
Science [ocdi] 0.000556827200984
tested [inpr] 0.000556766738305
Moderate [qlco] 0.000556430719921
progression [patf] 0.000556340882703
Beta-Blockers [phsu] 0.000554897375605
Concern [idcn] 0.000554487132667
rosuvastatin [orch, phsu] 0.000553864693106
Sample [sbst] 0.000553241603113
Measures [qnco] 0.000552152540788
Comparison [acty] 0.000551627130949
responses [orga] 0.000551111679343
Expression [topp] 0.000550853154678
Cost Effectiveness [qnco] 0.000550563179617
Few [qnco] 0.000547949347075
Alternative [cnce] 0.000547946852858
GENETIC [topp] 0.000544509530797
Calcium [bacs, elii, phsu] 0.000543923525563
Age-Years [tmco] 0.000543190539296
Arterial [bpoc] 0.000542982987188
Inhibition [menp] 0.000541863905065
Frequently [tmco] 0.000541673312527
Diet [food] 0.000541569749871
plasma concentration [qnco] 0.000541414371127
Onset [qlco] 0.000538513948704
diabetic [fndg] 0.000538078069717
Progesterone [horm, phsu, strd] 0.000536374486846
DOUBLE BLIND [resa] 0.00053571877701
General [spco] 0.000535606676802
Children [aggp] 0.000534898592957
adverse effects [ftcn] 0.000534541019674
secondary [neop] 0.000533170168688
Question [inpr] 0.00053281113977
Females [fndg] 0.000531754824296
Appropriate [qlco] 0.000529615457994
Radiation [npop] 0.000529181567681
Administered [ftcn] 0.000527968348522
repaglinide [orch, phsu] 0.000527227462355
Protection [fndg] 0.000525014688281
Initial [tmco] 0.000523072784667
Often [tmco] 0.000522949425886
Atrial Fibrillation [patf] 0.000521836875301
Physical activity [dora] 0.000519739011936
days [tmco] 0.000519616661834
Area [geoa] 0.000516769592651
Menopausal [phsf] 0.000515642845949
GY [geoa] 0.000515075508666
Mechanism [ftcn] 0.000514282566831
Active [ftcn] 0.000513886409384
Correlated [qlco] 0.000512228064969
Value [qnco] 0.000511913005416
topic5
Estrogen [horm, phsu, strd] 0.00391563331611
N NOS [aapp, imft] 0.00333551287078
C-reactive protein [aapp, imft] 0.00310684303934
mg% [qnco] 0.00285321559135
placebo [topp] 0.00277300093713
Stroke [dsyn] 0.00264748374061
Oral [spco] 0.00253956730269
Men [popg] 0.00225454757062
Lipid [lipd] 0.00217976077972
Diabetes [dsyn] 0.00205858645643
Survival [acty] 0.00205501128989
Recent [tmco] 0.00205249383174
Death [orgf] 0.00203121811653
coronary [bpoc] 0.00200988622064
Decreased [qnco] 0.00198685381926
Change [ftcn] 0.00196830301865
randomized [resa] 0.00195752128326
Blood Pressure [orgf] 0.00193071592919
Myocardial Infarction [dsyn] 0.00187848139457
Individual [popg] 0.00185982602154
Subject [grup] 0.00184825725588
Benefit [qnco] 0.00183210889681
Plasma [bdsu] 0.00181854726209
vascular [bpoc] 0.00180682402426
Raloxifene [orch, phsu] 0.00180444663987
Drug [phsu] 0.00176553422736
Old [tmco] 0.00175080852009
Cholesterol [bacs, strd] 0.00174117334281
Breast Cancer [neop] 0.00172045940783
Evaluated [ftcn] 0.00171895254675
Receive [qlco] 0.00170010922857
Marker [clna] 0.00168912084876
function [phsf] 0.00166260765098
R- [spco] 0.00164239925052
development [phsf] 0.0016317067434
Received [qlco] 0.00162326690207
Measured [qlco] 0.00162185006558
Response [orga] 0.00160143674536
Cancer [neop] 0.00159091862968
Atherosclerosis [dsyn] 0.00158697331
Overall [inpr] 0.001577838166
Decrease [qlco] 0.00156404765067
Confidence Interval [qnco] 0.0015476068067
Non [ftcn] 0.00154720342434
High Risk [qlco] 0.00152536334285
Endothelial [tisu] 0.00151729919779
Cases [ftcn] 0.00151705427819
Assess [acty] 0.00151182796206
Aged [orga] 0.00149381822504
Reported [inpr] 0.00148859043997
Body Mass Index [diap] 0.00147813605904
Current [tmco] 0.00146193794827
Early [tmco] 0.00145281839801
Menopause [phsf] 0.0014426768381
Similar [qlco] 0.00143240046764
Equal [qlco] 0.00142133147948
lowering [spco] 0.00141964082733
ischaemic heart disease [dsyn] 0.00141880196868
Plus [qlco] 0.00137830721129
Total Cholesterol [lbpr] 0.00137517098785
Complications [patf] 0.00135987092698
Dose [qnco] 0.00135948169049
weeks [tmco] 0.00135298891926
Elderly [popg] 0.00134176052753
Acute myocardial infarction [dsyn] 0.00132905891338
WHI [inpr] 0.0013212366142
coronary artery disease [dsyn] 0.00131404487951
Statin [orch, phsu] 0.00131218098371
IMPACT [gngm] 0.00130749576531
Article [inpr] 0.0012990259725
Events [evnt] 0.00129494114775
symptoms [ftcn] 0.00129010359839
Possible [qlco] 0.00128961149483
Users [humn] 0.00128863816402
Several [qnco] 0.00128484185391
Alone [qnco] 0.00128220269393
Concentrations [menp] 0.0012757626996
Drugs [phsu] 0.0012752088143
Heart disease [dsyn] 0.00126786698134
Hormone Therapy [topp] 0.0012495518003
Common [qnco] 0.0012479100749
Cardiac [bpoc] 0.0012311677483
LTD [ortf] 0.00122916415478
Large [qnco] 0.00122428889094
Sex [orgf] 0.00121567607324
Improvement [cnce] 0.00121461417223
Statins [orch, phsu] 0.00121072376118
Induced [ftcn] 0.00120532802514
Association [menp] 0.00119124219614
acute [tmco] 0.00118579807269
Agent [chvf] 0.00117683012708
Guidelines [inpr] 0.00117596121248
findings [ftcn] 0.00117181337295
Dependent [qlco] 0.00116821229929
Provide [acty] 0.00116617327224
low [qlco] 0.00116614292505
median [spco] 0.00115869529547
Prevalence [qnco] 0.00115803960997
Predictor [idcn] 0.00115602228438
I- [inch] 0.00115581031805
Combined [qlco] 0.00115067316323
Main [qlco] 0.00114871179401
radiotherapy [inpr] 0.00114047698691
practice [menp] 0.00113468675955
Specific [qlco] 0.0011301628459
Incidence [qnco] 0.00112584798235
Smoking [inbe] 0.00112547728865
Assessed [acty] 0.00112406525146
PREVENT [phsu] 0.00111930999717
Well [qlco] 0.00111532421791
Osteoporosis [dsyn] 0.00111453448644
Need [qlco] 0.0011042548885
mg dl [qnco] 0.00108849514296
Progestin [horm, phsu, strd] 0.00108749686362
Life [idcn] 0.00108372378039
intervention [hlca] 0.00108242979786
Triglycerides [bacs, lipd] 0.00107525613089
Heart [bpoc] 0.00106076013813
Care [acty] 0.00105457358697
Independent [idcn] 0.0010426077374
Estradiol [horm, phsu, strd] 0.00102998085092
Medical [ftcn] 0.00102756723067
Four [qnco] 0.00102112039298
Improved [qlco] 0.00101965188691
History [ocdi] 0.00101541790935
Drug Therapy [topp] 0.00100992851962
Reducing [qlco] 0.00100986769621
Administration [ocac] 0.00100816492375
Benefits [qnco] 0.00100647612865
Therapeutic [topp] 0.00100003514064
H+ [elii] 0.000994615853604
Elevated [qlco] 0.000991656755693
Low Density Lipoprotein Cholesterol [bacs, strd] 0.000987166710626
Range [qnco] 0.000986770494944
Combination [qlco] 0.000977080837301
mediated [socb] 0.000973087002805
variables [qlco] 0.000966468914893
Increasing [ftcn] 0.000965147663693
Conduct [inbe] 0.000963226076025
Values [qlco] 0.000962443058944
High Density Lipoprotein Cholesterol [bacs, lipd] 0.000962255488096
Make [ftcn] 0.000959736929961
setting [ftcn] 0.000957685172956
Presence [topp] 0.000956620326627
Adjusted [ftcn] 0.000951271769223
Safety [hcpp] 0.000946615331388
Purpose [ftcn] 0.000944261198907
diabetic [fndg] 0.000937579435374
Morbidity [qnco] 0.00093749571668
Parameters [fndg] 0.000936547807034
Needed [qlco] 0.000930904912913
experience [menp] 0.000928190850923
In [qnco] 0.000927131439384
Copyright [inpr] 0.000926507006643
Future [tmco] 0.000924920396665
Hormone [horm] 0.000917496305488
investigated [ftcn] 0.000913801006506
Associations [menp] 0.000903346150453
Available [ftcn] 0.000901864320446
cardiovascular risk factor [dsyn] 0.000896152135742
tibolone [phsu, strd] 0.000894300676303
condition [dsyn] 0.000890805783974
Affect [menp] 0.000888601499763
Percent [qnco] 0.000888158150844
considered [idcn] 0.000887996987602
Various [irda] 0.000887186622208
Clinical Trials [resa] 0.000880348196107
Daily [tmco] 0.000879492550237
Serum [bdsu] 0.000874433999271
Atrial Fibrillation [patf] 0.000867282114107
III [inpr] 0.000866741375674
Flow [npop] 0.00086446773928
Odds Ratio [qnco] 0.000862351147946
Type [qlco] 0.000861013151281
g% [qnco] 0.000860138786404
C-reactive protein level [lbpr] 0.000860050760547
Null [qnco] 0.000851363581346
Compare [acty] 0.000848161071514
Initiative [menp] 0.000847564879269
Aspirin [orch, phsu] 0.000845482414928
Addition [ftcn] 0.000838265998982
Conjugated estrogen [horm, phsu, strd] 0.000834497171874
Mechanisms [ftcn] 0.000833048803431
Fasting [fndg] 0.000832166977915
Endothelium [tisu] 0.000827301536438
rosuvastatin [orch, phsu] 0.00082551220627
Transdermal [ftcn] 0.000824267088681
Take [hlca] 0.000821401944463
Diagnosis [fndg] 0.000819985282831
Fibrinogen [aapp, bacs, phsu] 0.000819690977732
strategies [menp] 0.000819165399053
Profile [lbpr] 0.000818273496648
Information [idcn] 0.000817342428794
Cholesterol, LDL [bacs, strd] 0.000808285166455
Estrogens [horm, phsu, strd] 0.000802708914639
Average [qnco] 0.000802562315412
Exercise [dora] 0.000802034729216
Examined [fndg] 0.000800379515886
Assessment [hlca] 0.000799716948779
Gender [orga] 0.000798759753616
Seen [qlco] 0.000798657527343
Primary [qlco] 0.000794264203367
Evaluation [ftcn] 0.000792966412049
Identified [qlco] 0.00079169745091
Approach [spco] 0.000790179536803
rats [mamm] 0.00078815838837
influential [idcn] 0.000786988878467
Previous [tmco] 0.000784047423827
participants [popg] 0.000783146742986
Established [qlco] 0.000783123142702
GIVEN [cnce] 0.000780451512461
Secondary Prevention [topp] 0.000779593642657
national [inpr] 0.000778761928911
APPEAR [qlco] 0.000778215040306
Same [qlco] 0.000772419020084
Control Group [grup] 0.000771328857196
Index [inpr] 0.0007703916419
Concern [idcn] 0.000768596666085
Risks [qlco] 0.000768213478889
Obesity [dsyn] 0.000768114109746
Severe [qlco] 0.000768051187037
Relationship [qlco] 0.000767988705748
Published [ocac] 0.000765064562972
Insulin [aapp, horm, phsu] 0.000764732431564
Quality [qlco] 0.000763313582991
Known [qlco] 0.00076315580954
Ireland [geoa] 0.000761953352189
Contribute [acty] 0.000760583577044
Recommended [idcn] 0.000758646806688
cardiovascular events [fndg] 0.000758607195747
hypertensive [fndg] 0.000755731766737
Additional [ftcn] 0.000755195967523
Diet [food] 0.000753896057702
Comparison [acty] 0.000751425501513
Hospital [hcro, mnob] 0.000750567338957
Life Style [socb] 0.000750175757079
Dyslipidaemia [dsyn] 0.000748939510688
Following [tmco] 0.000745338169567
Single [popg] 0.000743827373958
investigate [ftcn] 0.000740104909868
Model [inpr] 0.000730292982976
Sclerotherapy [topp] 0.000730071573217
Long [qlco] 0.000728630364068
homocysteine [aapp, bacs] 0.000728548521191
Strong [qlco] 0.000728024285142
Likely [qlco] 0.000727065313616
Heart failure [dsyn] 0.000726653336943
Five [qnco] 0.000725537125896
mg day [qnco] 0.000722983768357
Concentration [menp] 0.000721574474753
Support [medd] 0.000712383603179
heart rate [clna] 0.000708372163707
Continuous [idcn] 0.000707195663398
Short-term [tmco] 0.000705520186103
mmHg [qnco] 0.000704248631402
Doses [qnco] 0.000703582094303
Low density lipoprotein [aapp, bacs, lipd] 0.000702927289095
Literature [inpr] 0.000700058850951
Risk factor [qnco] 0.000697176265341
Lipid-lowering therapy [topp] 0.00069606977836
Issue [fndg] 0.000693373837886
Children [aggp] 0.000693369624433
Characteristics [qlco] 0.000691908020036
Measures [qnco] 0.000690000904781
Target [ftcn] 0.000689843322585
prospective [resa] 0.000687966089094
Physicians [prog] 0.000680699291936
Ratio [qnco] 0.000678313132165
Medications [phsu] 0.000677298350841
Female [fndg] 0.000676848463024
Multiple [qnco] 0.000676709011931
Observational Study [resa] 0.000673856835811
Defined [cnce] 0.000667825198125
Surgery [bmod] 0.000666521366002
Cost [qnco] 0.000666427457766
medroxyprogesterone acetate [horm, phsu, strd] 0.000665702255699
???lead [elii, hops] 0.000665113156137
Prognosis [hlca] 0.000664377766059
System [ftcn] 0.000663466522564
Relative [famg] 0.000663383444816
Dietary [food] 0.000662474381846
Value [qnco] 0.000662373506218
Occur [acty] 0.000655209572065
Triglyceride [bacs, lipd] 0.000651466776222
Status [qlco] 0.000648688393899
Help [socb] 0.000646634306973
Lipids [lipd] 0.000642068623627
Discharge [bdsu] 0.000640811350034
reductions [npop] 0.00064032700295
Human [humn] 0.000639763485475
strategy [menp] 0.000635482622839
Initial [tmco] 0.000633644271084
Adult [aggp] 0.000630721650437
Very [qlco] 0.000630668243245
Cohort [popg] 0.000629154366038
Favorable [qlco] 0.000628180592563
Equine [mamm] 0.000627299975663
Select [acty] 0.000626196706043
Expression [topp] 0.000624428072047
Part [spco] 0.000624029725186
premenopausal [tmco] 0.000620430174309
Duration [tmco] 0.000617843965592
activity [dora] 0.000617772645196
Late [tmco] 0.000616160590298
Testosterone [horm, phsu, strd] 0.000615669872246
Bone Mineral Density [clna] 0.000614072542546
Often [tmco] 0.000613369999078
atorvastatin [orch, phsu] 0.000605014378062
Cost Effectiveness [qnco] 0.000603447483906
objectives [inpr] 0.000601107944962
Inflammatory [ftcn] 0.000599274773791
Variability [cnce] 0.000598811417291
Young [tmco] 0.000598503931577
Represent [acty] 0.000597037910499
prescribed [hlca] 0.000593668048768
Sample [sbst] 0.000593029913885
Ischaemic [ftcn] 0.000592576970259
Arterial [bpoc] 0.000591965358753
Direct [qlco] 0.000590846985443
Inflammation [patf] 0.000590679947118
Effectiveness [qlco] 0.00058962768759
Glucose [bacs, carb, phsu] 0.000589511852804
Score [qnco] 0.000588076768411
Screening [hlca] 0.00058668565311
HRT [topp] 0.000586309829037
Mechanism [ftcn] 0.000584204029242
Cardiovascular Diseases [dsyn] 0.000583927403448
Replacement [topp] 0.000581826186922
Hypercholesterolaemia [dsyn] 0.000580985440134
Relative Risk [qnco] 0.000580549661906
Correlated [qlco] 0.000580539963013
Exist [cnce] 0.000579742808838
Hypothesis [idcn] 0.000579237136131
Ischaemia [dsyn] 0.000575212696867
Treatments [topp] 0.000572112181166
Small [qnco] 0.000567515217263
General [spco] 0.000562219984848
chronic [tmco] 0.000562209131338
mmol/L [qnco] 0.000559987426965
Diseases [dsyn] 0.000558527780436
Second [qnco] 0.000558459132245
Types [qlco] 0.00055841571362
DOUBLE BLIND [resa] 0.000558283401976
Low dose [qnco] 0.000557485779229
Estrogen Replacement Therapy [topp] 0.000556722339648
measurements [ftcn] 0.000556476868013
Action [ftcn] 0.000555650496069
Chemoprevention [topp] 0.000553831650707
mg/L [qnco] 0.000553425087759
Modification [ftcn] 0.000552059545084
Novel [tmco] 0.000551911300861
Insulin Resistance [patf] 0.000549833245826
Leading [tmco] 0.000549020243316
Six [qnco] 0.000548545118288
Carotid [bpoc] 0.000547086818274
regimens [inpr] 0.000547086090944
Revealed [qlco] 0.000546575661557
Knowledge [inpr] 0.000545533621635
White [popg] 0.000543765272157
Optimal [qlco] 0.000543490352116
Chronic heart failure [dsyn] 0.000541716865202
Point [qnco] 0.000537913474458
Venous malformation [anab] 0.000536996711685
Progestins [horm, phsu, strd] 0.000536704287382
Angiotensin-Converting Enzyme Inhibitors [phsu] 0.000536536155235
Beta-Blockers [phsu] 0.000536346717406
days [tmco] 0.000536006681545
End [spco] 0.000534295278624
progression [patf] 0.000533938373624
Limited [ftcn] 0.000530985940995
Currently [tmco] 0.000526878160603
Understanding [menp] 0.00052260008869
Measure [qnco] 0.000521356756837
Lp(a) [aapp, bacs] 0.000519554782207
Syndromes, Acute Coronary [dsyn] 0.000519231750748
Physical activity [dora] 0.000518539065372
Better [qlco] 0.000518500537277
Simvastatin [orch, phsu] 0.00051735617614
Involved [ftcn] 0.000515904451169
deaths [orgf] 0.000515813414105
Irradiation [npop] 0.000515472350492
placebo-controlled [resa] 0.000513281856001
Atherogenesis [patf] 0.000513017466516
Adults [aggp] 0.000512412567952
Lung Cancer [neop] 0.000511912960655
Obtained [ftcn] 0.000511862401322
High density lipoprotein [aapp, bacs, lipd] 0.000511513529822
Estimated [qnco] 0.00051057755092
Case [ftcn] 0.000510396253464
account [idcn] 0.000508187054765
Administered [ftcn] 0.00050478253503
Adjustment [inbe] 0.000504612133587
Consecutive [qlco] 0.000503364996291
mice [mamm] 0.000502406943902
inhibitors [chvf] 0.000502261156704
Cycle [tmco] 0.000502074787086
Occurred [acty] 0.000500922980244
Conventional [qlco] 0.00049968954808
Method [inpr] 0.000499122617707
soy [food] 0.000498681316219
topic6
Estrogen [horm, phsu, strd] 0.00489711456361
N NOS [aapp, imft] 0.0041157152752
C-reactive protein [aapp, imft] 0.00291747792684
Men [popg] 0.00279631877229
Blood Pressure [orgf] 0.00271028337344
placebo [topp] 0.00262903308928
Stroke [dsyn] 0.00258220860721
R- [spco] 0.00239174825007
mg% [qnco] 0.00229794192595
Plasma [bdsu] 0.00226537685382
Death [orgf] 0.00218495401933
randomized [resa] 0.00207674608882
Received [qlco] 0.00203584090015
Association [menp] 0.00198526598303
Individual [popg] 0.00195124975654
Raloxifene [orch, phsu] 0.00191505696773
Early [tmco] 0.0019117382297
Measured [qlco] 0.00184145224058
Lipid [lipd] 0.00182113891715
coronary [bpoc] 0.00181366341958
Decrease [qlco] 0.00180888358019
Oral [spco] 0.00176061569791
Old [tmco] 0.00174315905082
Subject [grup] 0.00174205986936
Receive [qlco] 0.00172840631171
Atherosclerosis [dsyn] 0.00168444458543
vascular [bpoc] 0.00167422242927
Incidence [qnco] 0.00165116471758
Events [evnt] 0.00164805966241
Confidence Interval [qnco] 0.0016464504874
Diabetes [dsyn] 0.00164151948152
Serum [bdsu] 0.00163163780944
Menopause [phsf] 0.00162691753777
PREVENT [phsu] 0.00160161602665
Elderly [popg] 0.00159233753661
Cholesterol [bacs, strd] 0.00158589604799
Primary [qlco] 0.00158332260876
symptoms [ftcn] 0.00157869902591
Recent [tmco] 0.0015678644569
Combined [qlco] 0.00156070278298
findings [ftcn] 0.00155179096904
Profile [lbpr] 0.00153981784401
Benefit [qnco] 0.00151844127769
Smoking [inbe] 0.00150605709635
Current [tmco] 0.00149671249181
lowering [spco] 0.00148909816517
Similar [qlco] 0.00148158112825
Cardiac [bpoc] 0.00147438966761
Decreased [qnco] 0.00144765872895
Common [qnco] 0.00143483212878
Assess [acty] 0.00141177035696
Dose [qnco] 0.00140846653126
weeks [tmco] 0.00140157064453
Body Mass Index [diap] 0.00139625736031
Myocardial Infarction [dsyn] 0.00139614733863
Endothelial [tisu] 0.00137718473263
Drugs [phsu] 0.00136576886376
Aged [orga] 0.00136571971313
Marker [clna] 0.00135697989005
Therapeutic [topp] 0.00135536757966
Predictor [idcn] 0.00135372408463
Plus [qlco] 0.00134837668775
Statins [orch, phsu] 0.00134700734735
low [qlco] 0.00131721753054
Induced [ftcn] 0.00130984588463
High Density Lipoprotein Cholesterol [bacs, lipd] 0.00130506980539
coronary artery disease [dsyn] 0.00130419997577
Users [humn] 0.00129764657896
Response [orga] 0.00129746139947
Osteoporosis [dsyn] 0.00128002178097
Young [tmco] 0.00127863814357
Drug [phsu] 0.00126757289651
Cancer [neop] 0.00126718695696
Likely [qlco] 0.00126716744218
High Risk [qlco] 0.00126686016381
Estradiol [horm, phsu, strd] 0.00126638685734
Cases [ftcn] 0.00126575165936
radiotherapy [inpr] 0.00125586044401
Breast Cancer [neop] 0.00124441295606
Overall [inpr] 0.00124020159984
Provide [acty] 0.00123749976667
Well [qlco] 0.00123141902668
Model [inpr] 0.00122072662626
Evaluated [ftcn] 0.00121980145262
Change [ftcn] 0.00121902142261
Several [qnco] 0.00121746121669
HRT [topp] 0.00120123598833
Concentrations [menp] 0.00120118156551
Non [ftcn] 0.00120064990671
participants [popg] 0.00119940091712
Medical [ftcn] 0.00119792331785
Take [hlca] 0.00119681485188
Administration [ocac] 0.00119182521231
Available [ftcn] 0.00118855946763
Equal [qlco] 0.00118598953201
Agent [chvf] 0.00118528770831
function [phsf] 0.0011825435731
development [phsf] 0.0011649765778
Purpose [ftcn] 0.00116477842643
Benefits [qnco] 0.00116296546609
acute [tmco] 0.00114311192915
mg dl [qnco] 0.001141405059
Progestin [horm, phsu, strd] 0.00113845775642
Flow [npop] 0.00113587102152
Diagnosis [fndg] 0.00113536672521
Need [qlco] 0.00113479924131
Following [tmco] 0.00113186870856
Relationship [qlco] 0.00112670807582
IMPACT [gngm] 0.00112621145487
ischaemic heart disease [dsyn] 0.00112365857812
Drug Therapy [topp] 0.00111370526417
Acute myocardial infarction [dsyn] 0.00110832874308
Null [qnco] 0.00110540573007
Copyright [inpr] 0.00110324026864
Prevalence [qnco] 0.00108500183437
Specific [qlco] 0.00107802139452
Inflammation [patf] 0.00107699942411
Aspirin [orch, phsu] 0.00106629213412
Target [ftcn] 0.00106514916365
LTD [ortf] 0.00106002872851
Dependent [qlco] 0.00105673608128
Life [idcn] 0.00105175123949
Odds Ratio [qnco] 0.00103093782732
Quality [qlco] 0.00102130004447
Guidelines [inpr] 0.00102098342038
setting [ftcn] 0.00101944034653
Reported [inpr] 0.00101392098622
Support [medd] 0.00101019058948
tibolone [phsu, strd] 0.00100953582022
Known [qlco] 0.00100749046802
Transdermal [ftcn] 0.00100660025735
Range [qnco] 0.000999230733747
Future [tmco] 0.000998258145498
Parameters [fndg] 0.000993715279731
Heart disease [dsyn] 0.000993131324223
Identified [qlco] 0.000988085538227
Care [acty] 0.000986252013918
Morbidity [qnco] 0.0009862331273
investigated [ftcn] 0.000984447254784
Large [qnco] 0.00098339396572
History [ocdi] 0.000982719957051
Sex [orgf] 0.000980995747322
Mechanisms [ftcn] 0.000980702474137
Assessed [acty] 0.000977142895126
Survival [acty] 0.000976875922129
Triglycerides [bacs, lipd] 0.000969679500525
Adjusted [ftcn] 0.000969269361948
WHI [inpr] 0.000965962998484
Percent [qnco] 0.000962866319765
Complications [patf] 0.000961173783634
Statin [orch, phsu] 0.000960913654433
condition [dsyn] 0.000960358115619
Long [qlco] 0.000957388703267
Concentration [menp] 0.000951146785354
Risks [qlco] 0.000948673792522
Combination [qlco] 0.000946833295335
Alone [qnco] 0.000945010970187
Total Cholesterol [lbpr] 0.00094490999903
intervention [hlca] 0.000939800577746
Make [ftcn] 0.000932078850543
Low Density Lipoprotein Cholesterol [bacs, strd] 0.000931397616639
Heart [bpoc] 0.00093051560633
Heart failure [dsyn] 0.000921108887912
Status [qlco] 0.000919457099836
Information [idcn] 0.000919206861304
APPEAR [qlco] 0.000919077489433
Article [inpr] 0.000918353502495
Conduct [inbe] 0.000917704397211
Examined [fndg] 0.000912370611621
Values [qlco] 0.000907670698331
???lead [elii, hops] 0.000904897774826
I- [inch] 0.000900123810363
Improved [qlco] 0.000899704025339
considered [idcn] 0.000899486827799
Dyslipidaemia [dsyn] 0.000890835428931
Clinical Trials [resa] 0.000881948371864
GIVEN [cnce] 0.000880224864199
mediated [socb] 0.00087861950373
cardiovascular events [fndg] 0.000871872711946
Elevated [qlco] 0.000871570952028
Possible [qlco] 0.000866835018112
strategies [menp] 0.000866627649211
national [inpr] 0.000866475144609
Adjustment [inbe] 0.000863492149109
median [spco] 0.000862533050518
influential [idcn] 0.000859378798968
Type [qlco] 0.00085913180336
experience [menp] 0.000858468943743
Characteristics [qlco] 0.000858421995216
Published [ocac] 0.000854506494681
Equine [mamm] 0.000854173203659
homocysteine [aapp, bacs] 0.00085199980548
Estrogen Replacement Therapy [topp] 0.000849197342793
Estrogens [horm, phsu, strd] 0.00084401555523
Human [humn] 0.000839555222391
Affect [menp] 0.000838899988379
soy [food] 0.00083779388187
Previous [tmco] 0.000831664108405
H+ [elii] 0.000831286567189
Secondary Prevention [topp] 0.00083105416125
Score [qnco] 0.000830500172773
Main [qlco] 0.000829898340774
Initiative [menp] 0.000819164549486
Improvement [cnce] 0.000817704130217
Daily [tmco] 0.000815593075272
Contribute [acty] 0.000813542552634
Cholesterol, LDL [bacs, strd] 0.000809380083961
Four [qnco] 0.000807430026474
Independent [idcn] 0.000806538788867
Addition [ftcn] 0.000805464722904
medroxyprogesterone acetate [horm, phsu, strd] 0.000803852127922
Reducing [qlco] 0.000802805201557
Presence [topp] 0.000802073409691
Obesity [dsyn] 0.00079821707763
premenopausal [tmco] 0.000797922723113
Fasting [fndg] 0.000795703333786
prospective [resa] 0.000792176898232
Single [popg] 0.000791062762822
In [qnco] 0.000789353809484
C-reactive protein level [lbpr] 0.000788960692657
Multiple [qnco] 0.000787013858771
Dietary [food] 0.000785573566267
Venous malformation [anab] 0.000782681325971
Cohort [popg] 0.000781907092611
Various [irda] 0.000778584496118
mg day [qnco] 0.000775416080095
Compare [acty] 0.000772133459519
Currently [tmco] 0.000765269968324
Ratio [qnco] 0.000764856833449
Initial [tmco] 0.000762718596497
Index [inpr] 0.000761978021365
Approach [spco] 0.000760487518532
Average [qnco] 0.000759263972034
practice [menp] 0.000751531573624
Five [qnco] 0.000747364997742
progression [patf] 0.000740450045832
Risk factor [qnco] 0.000736450304585
investigate [ftcn] 0.000733720114092
Hormone Therapy [topp] 0.00072934197896
DOUBLE BLIND [resa] 0.000729134511897
Strong [qlco] 0.000728362092305
Small [qnco] 0.000723795048336
Severe [qlco] 0.000720505731788
measurements [ftcn] 0.000719890232976
hypertensive [fndg] 0.00071780636157
Assessment [hlca] 0.000715580655134
Control Group [grup] 0.000715453916763
Short-term [tmco] 0.000714103251262
reductions [npop] 0.000714023739026
Insulin [aapp, horm, phsu] 0.000712374413078
Safety [hcpp] 0.000712181085203
Better [qlco] 0.000710227853551
Frequently [tmco] 0.000704405171779
Relative [famg] 0.000703273666069
Surgery [bmod] 0.000699330608068
Observational Study [resa] 0.000698502793335
Additional [ftcn] 0.000695292002833
Part [spco] 0.000694009896725
Inflammatory [ftcn] 0.000687958610369
chronic [tmco] 0.000686808292393
Conjugated estrogen [horm, phsu, strd] 0.000685201738195
g% [qnco] 0.000683961602632
recommendations [idcn] 0.000682392035185
Associations [menp] 0.000681770503619
Sample [sbst] 0.00067931598423
Atrial Fibrillation [patf] 0.000674100692733
Continuous [idcn] 0.000672011755121
Duration [tmco] 0.000670422256044
Goal [inpr] 0.000656045911897
System [ftcn] 0.000654739212924
Hormone [horm] 0.000653600373053
Diet [food] 0.000652242659081
Atherogenesis [patf] 0.000651603000586
Needed [qlco] 0.000651141307419
Exercise [dora] 0.000645657764897
III [inpr] 0.000643644166342
Moderate [qlco] 0.000643609092252
Syndromes, Acute Coronary [dsyn] 0.000643051581559
Inhibition [menp] 0.000642399761581
Favorable [qlco] 0.000641487058193
variables [qlco] 0.000638867663881
Interaction [ftcn] 0.000636319109705
Ireland [geoa] 0.000634884644605
Seen [qlco] 0.000633067017066
Triglyceride [bacs, lipd] 0.000628644668394
Normal [qlco] 0.000628249062189
mmHg [qnco] 0.000624435845559
rats [mamm] 0.000624338471002
Measure [qnco] 0.000623754975021
Exist [cnce] 0.000623515447223
Comparison [acty] 0.000623336474862
Issue [fndg] 0.000609215913687
Involved [ftcn] 0.000607412149095
Recently [tmco] 0.000601825844861
Adult [aggp] 0.000601443566461
Action [ftcn] 0.000598860036943
Modification [ftcn] 0.000597853740977
Hospital [hcro, mnob] 0.00059664617723
Test [lbpr] 0.000595072558571
Mechanism [ftcn] 0.000594481247626
Hypothesis [idcn] 0.000591418883728
Correlation [qlco] 0.000591210864858
Variability [cnce] 0.000590461114623
regimens [inpr] 0.000589437479524
lesions [fndg] 0.00058879654428
Obtained [ftcn] 0.00058810205561
Very [qlco] 0.000583671490891
Fibrinogen [aapp, bacs, phsu] 0.000580872430264
Hospitalization [hlca] 0.000578730457687
Dilation [patf] 0.000575720132409
Progestins [horm, phsu, strd] 0.000575620289067
Knowledge [inpr] 0.000575218863699
Low density lipoprotein [aapp, bacs, lipd] 0.000574563948038
Direct [qlco] 0.000574317418399
month [tmco] 0.000574144319206
Screening [hlca] 0.000573982284063
cardiovascular risk factor [dsyn] 0.000573492606078
Post [tmco] 0.000571986523426
Relative Risk [qnco] 0.000570239027835
Chemoprevention [topp] 0.000570142507237
Hazard Ratio [qnco] 0.000569176399306
choice [inbe] 0.000568622498668
End [spco] 0.000568065862543
Concern [idcn] 0.000567125891684
Correlated [qlco] 0.00056543142565
account [idcn] 0.000565042211749
Testosterone [horm, phsu, strd] 0.000564737513313
Alternative [cnce] 0.00056464432053
Treatments [topp] 0.000563915927066
rosuvastatin [orch, phsu] 0.00056132197533
Gender [orga] 0.000556047536091
search [inpr] 0.000555191999898
MODIFY [ftcn] 0.000555015201973
Required [ftcn] 0.00055453418647
Same [qlco] 0.000553939266274
Evaluation [ftcn] 0.000553624345723
Class [inpr] 0.00055039051028
Cost [qnco] 0.000549751724202
Sclerotherapy [topp] 0.000547672103962
Protein [aapp, bacs] 0.000546944324127
Understanding [menp] 0.000545500506956
side effects [ftcn] 0.000544176313244
Physicians [prog] 0.000542483789954
Measures [qnco] 0.000542023364094
Bone Mineral Density [clna] 0.000540723108939
Science [ocdi] 0.000540073649889
Ischaemic [ftcn] 0.000539700967716
Children [aggp] 0.000539657516882
Point [qnco] 0.000538155329202
Literature [inpr] 0.000537543069556
Progesterone [horm, phsu, strd] 0.000537075370355
interventions [hlca] 0.000535262089537
statistically significant [qnco] 0.000535117553946
Glucose [bacs, carb, phsu] 0.000534622742453
Menopausal [phsf] 0.000534576430216
Increasing [ftcn] 0.000534084370912
Physical activity [dora] 0.000533209514203
activity [dora] 0.000530375738747
Late [tmco] 0.000529767675008
Prognostic Factor [clna] 0.000529290972622
Question [inpr] 0.00052832709401
Life Style [socb] 0.000528038837621
High density lipoprotein [aapp, bacs, lipd] 0.000527832981219
Medications [phsu] 0.000527342280385
Case [ftcn] 0.000526301321238
Endothelium [tisu] 0.00052532539438
Diseases [dsyn] 0.000523921530397
Replacement [topp] 0.000521622270698
Familial hypercholesterolaemia [dsyn] 0.000521505843438
Six [qnco] 0.000520923545946
Estimated [qnco] 0.000519834565464
Beta [plnt] 0.0005198230404
Lipoproteins [aapp, bacs] 0.00051442601527
lack [qlco] 0.000512821456155
Controlled [ftcn] 0.00051264160238
Administered [ftcn] 0.000512507561321
occurrence [ftcn] 0.000512342556392
strategy [menp] 0.000511544232987
atherosclerotic [ftcn] 0.000510767409693
TREAT [ftcn] 0.000508902590229
Select [acty] 0.000506167760113
Beta-Blockers [phsu] 0.000505830402594
Hypercholesterolaemia [dsyn] 0.000505584876719
Chronic heart failure [dsyn] 0.000504735571062
Global [spco] 0.000504214517065
General [spco] 0.000503023002904
Value [qnco] 0.000502208927038
diabetic [fndg] 0.00050170489763
confirmed [qlco] 0.000501609710803
Play [dora] 0.000500437723388
Intake [ftcn] 0.000499128634811
Lipids [lipd] 0.000498995783301
Genotype [orga] 0.000498762529237
Angiotensin-Converting Enzyme Inhibitors [phsu] 0.000498396962528
Defined [cnce] 0.000496005145291
Help [socb] 0.000495662113309
Lung Cancer [neop] 0.000495639112617
Approaches [spco] 0.000495462268572
Carotid [bpoc] 0.00049299769116
menopausal symptoms [sosy] 0.000492380011784
topic7
C-reactive protein [aapp, imft] 0.00409744518628
Estrogen [horm, phsu, strd] 0.00341633896645
Men [popg] 0.0033318408306
placebo [topp] 0.00284475445121
Diabetes [dsyn] 0.0028255304524
Blood Pressure [orgf] 0.00277057434003
mg% [qnco] 0.00274782364314
N NOS [aapp, imft] 0.00260542908758
Stroke [dsyn] 0.00229647954291
Subject [grup] 0.00224923253587
Recent [tmco] 0.00211253948958
Raloxifene [orch, phsu] 0.00209535630759
Change [ftcn] 0.00206840722735
Evaluated [ftcn] 0.00206081255934
Oral [spco] 0.00205486056664
Early [tmco] 0.00203135520277
randomized [resa] 0.00200865106491
Myocardial Infarction [dsyn] 0.0019695412662
Measured [qlco] 0.00194182730676
Confidence Interval [qnco] 0.00188119397743
Individual [popg] 0.0018302508678
Lipid [lipd] 0.00180932128643
Current [tmco] 0.0017857426377
Survival [acty] 0.00176821967894
Incidence [qnco] 0.00171255264597
Predictor [idcn] 0.00167823116844
coronary [bpoc] 0.00165616986354
Decreased [qnco] 0.00165105794394
Statins [orch, phsu] 0.00161801044231
Profile [lbpr] 0.00159639147687
High Risk [qlco] 0.0015903731131
Decrease [qlco] 0.0015814687744
Non [ftcn] 0.00157460799778
Similar [qlco] 0.00156809462258
Received [qlco] 0.00156757147484
Plasma [bdsu] 0.00156520747821
lowering [spco] 0.00155706260177
mg dl [qnco] 0.00155502323785
Assess [acty] 0.0015468858475
Events [evnt] 0.00152086562481
Body Mass Index [diap] 0.00152009736449
Endothelial [tisu] 0.00150507518092
Breast Cancer [neop] 0.00150336526368
Cancer [neop] 0.0014878584485
function [phsf] 0.00148408390768
Combined [qlco] 0.00148106469234
Association [menp] 0.00146560007188
Atherosclerosis [dsyn] 0.00146203669869
vascular [bpoc] 0.00145060753966
Cholesterol [bacs, strd] 0.00144686742595
symptoms [ftcn] 0.0014465046336
Death [orgf] 0.00144314998777
Marker [clna] 0.00142673674736
Menopause [phsf] 0.00141638212396
Statin [orch, phsu] 0.00141392560437
Old [tmco] 0.00139702387353
PREVENT [phsu] 0.00139543715427
Several [qnco] 0.00138771229191
Well [qlco] 0.0013793389299
Plus [qlco] 0.0013787770282
Equal [qlco] 0.00137207935592
Receive [qlco] 0.00137146051908
Improved [qlco] 0.00135764102118
Prevalence [qnco] 0.00134885619616
intervention [hlca] 0.00134080357366
Drug [phsu] 0.00133572379731
low [qlco] 0.00132736656083
Drugs [phsu] 0.00132503205008
Acute myocardial infarction [dsyn] 0.00132439444574
weeks [tmco] 0.00132369995273
Concentrations [menp] 0.00132354154901
Total Cholesterol [lbpr] 0.00129697879677
Benefit [qnco] 0.00128471458515
findings [ftcn] 0.00128121118141
Smoking [inbe] 0.00127273744614
Induced [ftcn] 0.00124806782178
Null [qnco] 0.00124764577708
development [phsf] 0.00124324367231
Progestin [horm, phsu, strd] 0.00123517989341
Possible [qlco] 0.00122658898064
Sex [orgf] 0.00122466051558
Values [qlco] 0.00122444953107
Available [ftcn] 0.00121480018563
coronary artery disease [dsyn] 0.00120114362151
Response [orga] 0.00119593918444
Affect [menp] 0.00119125663072
Life [idcn] 0.00118386684855
R- [spco] 0.00117905526522
LTD [ortf] 0.00117801354778
Range [qnco] 0.0011686382347
Complications [patf] 0.00116718598645
APPEAR [qlco] 0.00116518435384
Flow [npop] 0.00116427056353
IMPACT [gngm] 0.00116242762056
Estradiol [horm, phsu, strd] 0.00115659447449
Serum [bdsu] 0.00115171870894
Conduct [inbe] 0.00115021911053
Heart disease [dsyn] 0.00114187873615
Drug Therapy [topp] 0.00114074088775
ischaemic heart disease [dsyn] 0.00113033999833
Assessed [acty] 0.00112787505683
Independent [idcn] 0.00112766165933
cardiovascular risk factor [dsyn] 0.00112467389929
History [ocdi] 0.00111752060516
Elevated [qlco] 0.00111126674984
tibolone [phsu, strd] 0.00110413711797
Dose [qnco] 0.00109613631086
Secondary Prevention [topp] 0.00108957504436
Specific [qlco] 0.00108630877375
Guidelines [inpr] 0.00108208214694
Agent [chvf] 0.00107593950354
Overall [inpr] 0.00106904734545
considered [idcn] 0.00106360445484
mediated [socb] 0.00106071303972
Type [qlco] 0.00105258380342
High Density Lipoprotein Cholesterol [bacs, lipd] 0.00105221110424
Alone [qnco] 0.00104528482811
Known [qlco] 0.00104146321429
Aged [orga] 0.00104099090803
Initiative [menp] 0.00103792938273
Make [ftcn] 0.00102937218649
Therapeutic [topp] 0.00102657765765
Hormone Therapy [topp] 0.00101997652948
acute [tmco] 0.00101620248037
Cardiac [bpoc] 0.00100335813851
hypertensive [fndg] 0.00100124075884
WHI [inpr] 0.00100040281731
Reported [inpr] 0.000999768696234
Heart failure [dsyn] 0.000999510871593
Osteoporosis [dsyn] 0.000997270095303
Large [qnco] 0.00099705030017
Article [inpr] 0.000995589143353
Medical [ftcn] 0.000993643175658
Relationship [qlco] 0.00098855572661
Aspirin [orch, phsu] 0.000987950565562
Take [hlca] 0.000981519899228
variables [qlco] 0.000981448720915
Concentration [menp] 0.00097637197688
Users [humn] 0.000974688466626
Identified [qlco] 0.000972252445537
influential [idcn] 0.000970132981212
Benefits [qnco] 0.000961307376427
Odds Ratio [qnco] 0.000957289420003
Common [qnco] 0.000955573972075
Fasting [fndg] 0.000954584816087
radiotherapy [inpr] 0.000949490721892
median [spco] 0.000943470704193
Following [tmco] 0.000942945139822
Cases [ftcn] 0.000938267518246
Adjusted [ftcn] 0.000937903161829
Diagnosis [fndg] 0.000933230214152
Heart [bpoc] 0.0009325236308
Cholesterol, LDL [bacs, strd] 0.000926750364037
GIVEN [cnce] 0.000925954469795
Clinical Trials [resa] 0.000921129837226
activity [dora] 0.000919626183065
investigated [ftcn] 0.000909401953336
Improvement [cnce] 0.000907488427513
Previous [tmco] 0.00090485998163
Mechanisms [ftcn] 0.000902527707831
Status [qlco] 0.000901788037339
Future [tmco] 0.000900907162613
I- [inch] 0.000898354961889
Elderly [popg] 0.000896600792995
Quality [qlco] 0.000895925449904
Combination [qlco] 0.000890816613277
Dependent [qlco] 0.000887580961495
Daily [tmco] 0.000883539404344
Ireland [geoa] 0.000882374624857
Purpose [ftcn] 0.00087858381253
Atrial Fibrillation [patf] 0.00087794806291
national [inpr] 0.000875276409113
Recommended [idcn] 0.000873464002546
Severe [qlco] 0.00086771944599
Safety [hcpp] 0.000866837636546
investigate [ftcn] 0.000863728496691
Young [tmco] 0.000862694076067
Four [qnco] 0.000862584221424
Main [qlco] 0.000861574593732
Addition [ftcn] 0.000860681962643
Target [ftcn] 0.000852300547166
Risk factor [qnco] 0.000847851367399
Reducing [qlco] 0.000847045546267
Obesity [dsyn] 0.000846068455345
Need [qlco] 0.000844602361182
Various [irda] 0.000843946403121
HRT [topp] 0.000839240107788
Cohort [popg] 0.000829835974341
???lead [elii, hops] 0.000826618148535
Model [inpr] 0.00082540713338
Method [inpr] 0.000823764692516
Published [ocac] 0.000821281356225
Low Density Lipoprotein Cholesterol [bacs, strd] 0.000819576279687
setting [ftcn] 0.000818934615372
Additional [ftcn] 0.000817506330606
Modification [ftcn] 0.000810826272605
Inflammation [patf] 0.000809730176322
Index [inpr] 0.000809696734255
Triglycerides [bacs, lipd] 0.0008070085439
Inhibition [menp] 0.000803061157815
Provide [acty] 0.000803018865479
Inflammatory [ftcn] 0.000796607461657
Estrogens [horm, phsu, strd] 0.000796024472317
Administration [ocac] 0.000793232314724
Support [medd] 0.000784779565007
Transdermal [ftcn] 0.000784487171207
Very [qlco] 0.000783229443519
homocysteine [aapp, bacs] 0.000782394239015
Assessment [hlca] 0.00078230850435
Insulin [aapp, horm, phsu] 0.000781680256632
Relative Risk [qnco] 0.000781575114223
Literature [inpr] 0.000781044918471
Copyright [inpr] 0.000779644924777
Approach [spco] 0.000776059660268
H+ [elii] 0.000774372581566
Cost [qnco] 0.000772167549688
Average [qnco] 0.000762940477809
Likely [qlco] 0.000762832075166
Low density lipoprotein [aapp, bacs, lipd] 0.000759219018139
experience [menp] 0.00075853935073
Short-term [tmco] 0.000757828921487
Beta-Blockers [phsu] 0.000756781585322
Part [spco] 0.000751583719264
Variability [cnce] 0.000749974562163
Primary [qlco] 0.000749491299866
Life Style [socb] 0.000743750087724
Dietary [food] 0.000741979228693
Observational Study [resa] 0.000741321634023
Compare [acty] 0.000733402589363
Physicians [prog] 0.0007329228931
C-reactive protein level [lbpr] 0.000731684391507
Hormone [horm] 0.000730950803472
Children [aggp] 0.000726642950262
Female [fndg] 0.000724648347755
Control Group [grup] 0.000723910647278
Alternative [cnce] 0.000721356149028
Fibrinogen [aapp, bacs, phsu] 0.000718983466832
Exercise [dora] 0.000717500397406
strategies [menp] 0.000716937101168
Needed [qlco] 0.000707939197597
Dyslipidaemia [dsyn] 0.000705581046178
Relative [famg] 0.000705246244865
Conjugated estrogen [horm, phsu, strd] 0.00070505770814
premenopausal [tmco] 0.000704872721175
Risks [qlco] 0.000703871933061
Increasing [ftcn] 0.000703686618423
lack [qlco] 0.000702794443295
Morbidity [qnco] 0.00070217938803
Percent [qnco] 0.000702059311977
medroxyprogesterone acetate [horm, phsu, strd] 0.000701050085004
participants [popg] 0.000700700377766
Parameters [fndg] 0.000698009216515
Presence [topp] 0.000693720021017
Care [acty] 0.000693182984357
Strong [qlco] 0.00068782666234
Ischaemic [ftcn] 0.000686896719828
account [idcn] 0.000686170795
measurements [ftcn] 0.000683915698049
Recently [tmco] 0.000683153608397
DOUBLE BLIND [resa] 0.000682839520092
Established [qlco] 0.000682225205415
Regimen [topp] 0.000680385151839
Small [qnco] 0.000676723459829
objectives [inpr] 0.000673756991174
Same [qlco] 0.000673233386283
progression [patf] 0.000671777724972
Ratio [qnco] 0.000669361402457
Diet [food] 0.000669112527225
Second [qnco] 0.000666830542939
Estrogen Replacement Therapy [topp] 0.000666025577423
condition [dsyn] 0.000662495115618
Progesterone [horm, phsu, strd] 0.000659225422232
Lung Cancer [neop] 0.000654407617154
Measure [qnco] 0.000653154733286
Occur [acty] 0.000651927730446
reductions [npop] 0.000646014179334
Lipids [lipd] 0.000643582822079
Continue [idcn] 0.000641959163458
reviewed [inpr] 0.000641612902962
Favorable [qlco] 0.000640999845271
Five [qnco] 0.000639365039441
inhibitors [chvf] 0.000638917359052
Equine [mamm] 0.000638507698393
mice [mamm] 0.000638377996547
Cost Effectiveness [qnco] 0.000637495907072
High density lipoprotein [aapp, bacs, lipd] 0.000636987861973
Better [qlco] 0.000636621548027
Triglyceride [bacs, lipd] 0.000635803573503
Treatments [topp] 0.0006339843342
mg day [qnco] 0.000632005493388
properties [qlco] 0.000629217631626
Sample [sbst] 0.000628453934276
Associations [menp] 0.000625250554038
Multiple [qnco] 0.000625108260515
System [ftcn] 0.000624106447836
depend [medd] 0.000622668904114
Leading [tmco] 0.000622556773858
plasma concentration [qnco] 0.0006215167957
Action [ftcn] 0.000620732392792
Hospital [hcro, mnob] 0.000617407756413
Limited [ftcn] 0.000616694141766
Often [tmco] 0.000616399410354
Endothelium [tisu] 0.00061556091053
Moderate [qlco] 0.000614476360705
rats [mamm] 0.00061281834779
In [qnco] 0.000612026902028
Surgery [bmod] 0.000609067735001
Characteristics [qlco] 0.000607757186698
search [inpr] 0.00060771748776
Appropriate [qlco] 0.00060714298155
Duration [tmco] 0.000606074710887
chronic [tmco] 0.000605334033993
Venous malformation [anab] 0.000603306278848
Initial [tmco] 0.000602651835734
menopausal symptoms [sosy] 0.000601930424893
Direct [qlco] 0.000596361374306
Contribute [acty] 0.000595666683919
Replacement [topp] 0.000593632646016
Mechanism [ftcn] 0.000591853329064
III [inpr] 0.000588557857467
Now [tmco] 0.000587603344454
Testosterone [horm, phsu, strd] 0.000587292752985
Chemoprevention [topp] 0.000585561054542
Syndromes, Acute Coronary [dsyn] 0.00058475835827
Seen [qlco] 0.0005838383049
Issue [fndg] 0.000582079035669
Continuous [idcn] 0.000580663858599
heart rate [clna] 0.000579213807232
prospective [resa] 0.000578609886599
Report [inpr] 0.000578018271064
Human [humn] 0.000574580753896
Question [inpr] 0.000574388300893
Long [qlco] 0.00057260175217
Start [tmco] 0.000571446552404
Protection [fndg] 0.000568001841257
Value [qnco] 0.000567365631681
Correlated [qlco] 0.000565284666832
Cardiovascular Diseases [dsyn] 0.000564773255154
prescribed [hlca] 0.0005644553624
cardiovascular events [fndg] 0.000563380998587
mmHg [qnco] 0.000563058051628
Late [tmco] 0.000561527129261
Diseases [dsyn] 0.000555571161268
Examined [fndg] 0.000555007536518
Novel [tmco] 0.000554604819905
Occurred [acty] 0.000554511233804
Past [tmco] 0.000554155663959
deaths [orgf] 0.000551856741466
Adult [aggp] 0.000551211546017
statistically significant [qnco] 0.000551131596071
Interaction [ftcn] 0.000551042497831
Screening [hlca] 0.000549904316586
Involved [ftcn] 0.000548784562137
American [popg] 0.000548028245637
Complex [qlco] 0.000546096527814
practice [menp] 0.000545287526008
Negative [qlco] 0.000545143540271
Indicated [fndg] 0.00054260691365
diabetic [fndg] 0.000540715052696
Lipid-lowering therapy [topp] 0.000540002843223
Area [geoa] 0.000539644927417
interventions [hlca] 0.000536552432475
Defined [cnce] 0.000533956552233
Evaluation [ftcn] 0.000533452276836
atorvastatin [orch, phsu] 0.000532483188308
Beta [plnt] 0.000532074503348
regimens [inpr] 0.000531189732214
Information [idcn] 0.000530659282011
Expression [topp] 0.000530229651254
Progestins [horm, phsu, strd] 0.000528970559089
High sensitivity [lbpr] 0.000528313531407
Sclerotherapy [topp] 0.000527669590467
Calcium [bacs, elii, phsu] 0.000526225587795
Vascular Malformations [anab] 0.000525746756122
lesions [fndg] 0.000525281285797
Revealed [qlco] 0.000525101134752
Hypothesis [idcn] 0.000523006416704
secondary [neop] 0.000522300848466
days [tmco] 0.000521611649715
Blood [tisu] 0.000518943188955
Good [qlco] 0.000518732491
Carotid [bpoc] 0.000515743941259
Link [inpr] 0.000515377150302
Frequently [tmco] 0.000515106096859
If [qlco] 0.000513009091631
Sensitivity [qnco] 0.000511793469364
Select [acty] 0.00051065978494
Isoflavones [orch, phsu] 0.000510363528665
mg/L [qnco] 0.000510314841806
formation [biof] 0.00050917129671
Simvastatin [orch, phsu] 0.000506496501068
Cholesterol, HDL [bacs, lipd] 0.000505153625965
Affected [ftcn] 0.000503784302954
choice [inbe] 0.000503465295111
Currently [tmco] 0.000502972545524
GENETIC [topp] 0.000502213594679
Wide [spco] 0.000501954437893
Medications [phsu] 0.000501688730776
Metabolic syndrome [dsyn] 0.000501586895498
Females [fndg] 0.000500999729795
topic8
C-reactive protein [aapp, imft] 0.00387334418655
Estrogen [horm, phsu, strd] 0.00364922710629
N NOS [aapp, imft] 0.00319284343413
mg% [qnco] 0.00276655335566
Blood Pressure [orgf] 0.00269049092437
Diabetes [dsyn] 0.00251605131819
Confidence Interval [qnco] 0.00241809383505
Stroke [dsyn] 0.00232107907682
Men [popg] 0.00228034396346
Oral [spco] 0.00227523168939
Decrease [qlco] 0.00208642796346
Measured [qlco] 0.00206268248912
Plasma [bdsu] 0.00194849771198
placebo [topp] 0.00193250001085
Similar [qlco] 0.00193240948987
Decreased [qnco] 0.0019078166263
Individual [popg] 0.00185021303148
Dose [qnco] 0.00184457223926
Myocardial Infarction [dsyn] 0.00182925716508
Death [orgf] 0.0018210133964
Benefit [qnco] 0.00179566512984
Menopause [phsf] 0.00176432232949
Evaluated [ftcn] 0.00175762209353
Cardiac [bpoc] 0.00175410037144
Non [ftcn] 0.00168940437292
Atherosclerosis [dsyn] 0.00168725854217
Cholesterol [bacs, strd] 0.00167951032436
Lipid [lipd] 0.00167759785571
symptoms [ftcn] 0.00167066361486
Receive [qlco] 0.00166778484892
Association [menp] 0.0016530037979
Current [tmco] 0.00163528587644
Statins [orch, phsu] 0.00163205237413
Early [tmco] 0.00157234553183
Marker [clna] 0.00155817588394
Received [qlco] 0.00155058180742
Subject [grup] 0.00154117822728
development [phsf] 0.00152184769422
Old [tmco] 0.0015191440061
Overall [inpr] 0.00151066942529
function [phsf] 0.00150352055172
High Risk [qlco] 0.00145640752122
Raloxifene [orch, phsu] 0.00145156614641
Concentrations [menp] 0.0014413419771
Drug [phsu] 0.00143432900033
Serum [bdsu] 0.0014334304917
Induced [ftcn] 0.0014275551316
randomized [resa] 0.00142675837038
Events [evnt] 0.00140682720674
Article [inpr] 0.00139691875716
Benefits [qnco] 0.00139589719596
Breast Cancer [neop] 0.00139354512504
Incidence [qnco] 0.00137475030846
R- [spco] 0.00137320094755
PREVENT [phsu] 0.00136821388034
Body Mass Index [diap] 0.00136616117629
Fasting [fndg] 0.00136189002164
Odds Ratio [qnco] 0.00135205684136
Recent [tmco] 0.0013503496663
Known [qlco] 0.00134958231215
Acute myocardial infarction [dsyn] 0.00134181109283
Response [orga] 0.00133186555002
Progestin [horm, phsu, strd] 0.00133112379754
vascular [bpoc] 0.00132335399834
Cancer [neop] 0.00131374530084
coronary artery disease [dsyn] 0.00130130314872
Drugs [phsu] 0.00129611993855
Values [qlco] 0.00129511569111
weeks [tmco] 0.00129325845844
practice [menp] 0.00129032586288
lowering [spco] 0.00128755554608
Combined [qlco] 0.0012773894156
Cases [ftcn] 0.00127234184895
Aged [orga] 0.00126567071783
Improved [qlco] 0.00125694882407
Specific [qlco] 0.00124701835622
Target [ftcn] 0.00123787060642
Agent [chvf] 0.0012347696702
Guidelines [inpr] 0.00123471706922
Several [qnco] 0.00123009690308
Alone [qnco] 0.00122720073189
coronary [bpoc] 0.00121339747695
Total Cholesterol [lbpr] 0.00120671895546
intervention [hlca] 0.00120235729018
Take [hlca] 0.00119791522036
Diet [food] 0.0011965745543
Common [qnco] 0.00119590265765
Provide [acty] 0.00119099653378
IMPACT [gngm] 0.00118229323039
Range [qnco] 0.0011808824006
Following [tmco] 0.00117722481245
Survival [acty] 0.00117710611233
Assess [acty] 0.00117076879402
Diagnosis [fndg] 0.0011643478553
Assessed [acty] 0.00115798182151
Need [qlco] 0.00115423778915
Predictor [idcn] 0.0011502306237
Profile [lbpr] 0.00114847667995
median [spco] 0.00114424220766
Life [idcn] 0.00114296422158
Users [humn] 0.00113590108128
Smoking [inbe] 0.00113225166151
ischaemic heart disease [dsyn] 0.00113193249974
low [qlco] 0.00111963006634
Plus [qlco] 0.00111920176199
condition [dsyn] 0.00111713344082
considered [idcn] 0.00110857315219
radiotherapy [inpr] 0.00110501605431
Possible [qlco] 0.0010982929131
Medical [ftcn] 0.00109478358651
Large [qnco] 0.00108863344393
Transdermal [ftcn] 0.001086431174
Null [qnco] 0.0010809880075
Reported [inpr] 0.00107747226812
mg dl [qnco] 0.00107245879896
Elderly [popg] 0.00106938419306
Concentration [menp] 0.00106022992608
findings [ftcn] 0.0010576995016
Change [ftcn] 0.00105685827832
WHI [inpr] 0.00105569130097
LTD [ortf] 0.00104648710022
Statin [orch, phsu] 0.00104628644815
Therapeutic [topp] 0.0010386801219
History [ocdi] 0.00103551314083
Conduct [inbe] 0.00103281973335
Four [qnco] 0.00102971372568
Venous malformation [anab] 0.00102671387431
Cost [qnco] 0.00102328431037
High Density Lipoprotein Cholesterol [bacs, lipd] 0.00101795339506
Prevalence [qnco] 0.001004618627
acute [tmco] 0.000995246559987
Drug Therapy [topp] 0.000995107670393
medroxyprogesterone acetate [horm, phsu, strd] 0.000993381267345
Equal [qlco] 0.000986053453642
Published [ocac] 0.000982205380734
Heart [bpoc] 0.000974705049189
Inflammation [patf] 0.000972650495558
Young [tmco] 0.000957543317359
Status [qlco] 0.00095425489016
Administration [ocac] 0.000953767382865
Cholesterol, LDL [bacs, strd] 0.000953635163255
Well [qlco] 0.000953546270504
participants [popg] 0.000953146396137
Estrogens [horm, phsu, strd] 0.000952635873382
Sex [orgf] 0.000952604013327
Type [qlco] 0.00094724794584
DOUBLE BLIND [resa] 0.000945785432397
Combination [qlco] 0.000944115702741
objectives [inpr] 0.000943387106822
Single [popg] 0.000938584798714
Equine [mamm] 0.000937794325446
Part [spco] 0.000935791255305
Affect [menp] 0.000934181454229
variables [qlco] 0.000931398306566
Care [acty] 0.000925463238882
Complications [patf] 0.000920040266708
Heart disease [dsyn] 0.00091283639838
Morbidity [qnco] 0.000911738723271
Purpose [ftcn] 0.000911050166317
Addition [ftcn] 0.000909307856647
Clinical Trials [resa] 0.000906906744703
Risks [qlco] 0.000906689632396
Estradiol [horm, phsu, strd] 0.000899327671342
setting [ftcn] 0.000899266851975
Dependent [qlco] 0.000898728053263
Improvement [cnce] 0.000897719855929
H+ [elii] 0.000894531580255
Available [ftcn] 0.000884997722556
Independent [idcn] 0.000883955059276
Very [qlco] 0.000864925074715
prospective [resa] 0.000863554215881
Aspirin [orch, phsu] 0.000860330775302
???lead [elii, hops] 0.000858376226038
Endothelium [tisu] 0.000849427471872
Identified [qlco] 0.000847552466099
Heart failure [dsyn] 0.00084358537092
Various [irda] 0.00084295206109
Assessment [hlca] 0.000839237601653
Elevated [qlco] 0.000837542770548
Exercise [dora] 0.000833648431733
activity [dora] 0.000833609866569
national [inpr] 0.000833504339051
Sclerotherapy [topp] 0.000828669269064
mediated [socb] 0.000822944538917
Physicians [prog] 0.000821799448751
Hormone [horm] 0.000820230507741
HRT [topp] 0.000818905769177
Secondary Prevention [topp] 0.000816920547466
Human [humn] 0.000815790221835
Examined [fndg] 0.000814094976917
mmHg [qnco] 0.000812992450689
GIVEN [cnce] 0.000812297584441
Action [ftcn] 0.000810424805388
homocysteine [aapp, bacs] 0.000808980055337
Approach [spco] 0.000804912213016
Lipids [lipd] 0.000798350988437
rats [mamm] 0.00078961998297
Osteoporosis [dsyn] 0.000786776180931
Hormone Therapy [topp] 0.000786330005423
Endothelial [tisu] 0.000786123384238
Recently [tmco] 0.000785506678535
Mechanisms [ftcn] 0.000783831883074
Low Density Lipoprotein Cholesterol [bacs, strd] 0.00078363224531
strategies [menp] 0.000782426213828
Conjugated estrogen [horm, phsu, strd] 0.000782226840871
Seen [qlco] 0.000781849420744
System [ftcn] 0.000781274187494
influential [idcn] 0.00078124084908
Information [idcn] 0.000779361586287
Female [fndg] 0.000776888304536
Better [qlco] 0.000775708144304
Safety [hcpp] 0.000775665034181
Triglycerides [bacs, lipd] 0.000769977750565
Late [tmco] 0.000768053733076
APPEAR [qlco] 0.000767476837089
hypertensive [fndg] 0.000767045363614
month [tmco] 0.000764434896662
diabetic [fndg] 0.000759889689749
investigate [ftcn] 0.000757047064423
Index [inpr] 0.000750470665708
Reducing [qlco] 0.000747706456421
Same [qlco] 0.000747279226205
Therapies [topp] 0.000742636472169
Model [inpr] 0.000742593807643
Main [qlco] 0.000742375811926
Future [tmco] 0.00074207104374
premenopausal [tmco] 0.000740902637112
Compare [acty] 0.000739884772147
Dietary [food] 0.000739191575196
Percent [qnco] 0.000737942734253
Likely [qlco] 0.000735937153157
Needed [qlco] 0.000735160094352
heart rate [clna] 0.000734428379962
Quality [qlco] 0.000729179816322
Average [qnco] 0.00072769781265
Prognosis [hlca] 0.000721047682685
Copyright [inpr] 0.000718281312911
White [popg] 0.000716458994212
In [qnco] 0.000715701927998
Previous [tmco] 0.000707536632055
recommendations [idcn] 0.000705561993792
Five [qnco] 0.000703918269688
Additional [ftcn] 0.000702854808527
Multiple [qnco] 0.000702670039991
Mechanism [ftcn] 0.00070027048152
Flow [npop] 0.000699681271028
Primary [qlco] 0.000698104334616
Lp(a) [aapp, bacs] 0.000696542738163
Measure [qnco] 0.000694916491363
g% [qnco] 0.000693541819222
Parameters [fndg] 0.000692546764616
Concern [idcn] 0.000691058984712
Short-term [tmco] 0.000690844477791
experience [menp] 0.000689658430243
Obesity [dsyn] 0.000687327847721
Support [medd] 0.000685198986497
Presence [topp] 0.000684117383705
Dyslipidaemia [dsyn] 0.000679722229347
Relationship [qlco] 0.000676587163009
Severe [qlco] 0.000676508022801
C-reactive protein level [lbpr] 0.000670060121502
Recommended [idcn] 0.000669830203242
Atrial Fibrillation [patf] 0.00066891832824
cardiovascular events [fndg] 0.000666939622625
tibolone [phsu, strd] 0.000664834694887
Initiative [menp] 0.000664102428822
Hospital [hcro, mnob] 0.000661833941363
Required [ftcn] 0.000659234745739
Duration [tmco] 0.000658038505919
Estrogen Replacement Therapy [topp] 0.000655696450853
Phytoestrogens [horm, phsu, strd] 0.00065521863805
Contribute [acty] 0.000653550349952
I- [inch] 0.000653128442581
days [tmco] 0.000652201928466
Fibrinogen [aapp, bacs, phsu] 0.000651470834534
Negative [qlco] 0.000651168638603
Leading [tmco] 0.000650840479834
Literature [inpr] 0.000647671047695
mmol/L [qnco] 0.000646606163
lesions [fndg] 0.000646161902488
Ireland [geoa] 0.000643910993516
High density lipoprotein [aapp, bacs, lipd] 0.000642502546419
deaths [orgf] 0.000641994464451
Long [qlco] 0.000639532589537
Lipid-lowering therapy [topp] 0.00063813626698
rosuvastatin [orch, phsu] 0.000637484595652
Method [inpr] 0.000634338578617
Currently [tmco] 0.000633589695513
Occurred [acty] 0.000633040367079
General [spco] 0.000632072431858
Low dose [qnco] 0.000628141908954
confirmed [qlco] 0.000624050929784
Gender [orga] 0.000623927027125
regimens [inpr] 0.00062127924321
Interaction [ftcn] 0.000619898340873
Expression [topp] 0.000619326861448
Doses [qnco] 0.00061894283315
investigated [ftcn] 0.000618002401341
Increasing [ftcn] 0.000617876426731
Help [socb] 0.000617763111214
soy [food] 0.000616740780246
Arterial [bpoc] 0.000615731443231
Understanding [menp] 0.000609638143084
Make [ftcn] 0.000607675514714
Science [ocdi] 0.00060593081736
Surgery [bmod] 0.000603740101819
Established [qlco] 0.000603164660426
Strong [qlco] 0.000601939908959
Ischaemic [ftcn] 0.000600843142368
Defined [cnce] 0.000598593539346
Relevant [qlco] 0.00059857443343
Variability [cnce] 0.00059808640434
cardiovascular risk factor [dsyn] 0.000594699718807
Age-Years [tmco] 0.000594534317276
Continuous [idcn] 0.000592686699159
Adjusted [ftcn] 0.000590544059615
lack [qlco] 0.000589402585482
Treatments [topp] 0.000588056797342
Favorable [qlco] 0.000584749844964
Tamoxifen [orch, phsu] 0.000584361594257
Genotype [orga] 0.00058393615974
Relative Risk [qnco] 0.000582628560812
Calcium [bacs, elii, phsu] 0.000581165217985
Control Group [grup] 0.000580562116721
atorvastatin [orch, phsu] 0.000575401904906
Frequently [tmco] 0.000574074317286
Initial [tmco] 0.000572741648207
Children [aggp] 0.000571425789545
Direct [qlco] 0.000567295209573
Simvastatin [orch, phsu] 0.000567255062318
Blood [tisu] 0.000563994330032
admission [hlca] 0.000563766184111
Class [inpr] 0.000562681100538
Ratio [qnco] 0.00056166641268
Relative [famg] 0.000558749109135
progression [patf] 0.000556559534531
Adult [aggp] 0.00055517066412
matched [resa] 0.000552406118452
reductions [npop] 0.000552087705303
secondary [neop] 0.000550472225051
Life Style [socb] 0.000547289155096
Conventional [qlco] 0.000544789392037
Test [lbpr] 0.000543457492677
Progestins [horm, phsu, strd] 0.000543202952397
Insulin [aapp, horm, phsu] 0.000541342000623
Event [evnt] 0.00053999168961
Pravastatin [orch, phsu] 0.00053786254839
Evaluation [ftcn] 0.00053692932056
Cohort [popg] 0.000535882793411
Correlated [qlco] 0.000535531182659
Syndromes, Acute Coronary [dsyn] 0.000532800925841
statistically significant [qnco] 0.000532312671793
Few [qnco] 0.00053128138557
Issue [fndg] 0.000530960644947
inhibitors [chvf] 0.000530397885274
Females [fndg] 0.000529141765908
Enhanced [acty] 0.000526883635788
Authors [prog] 0.000525756651027
Value [qnco] 0.000525718901925
Severity [qlco] 0.000523949162802
Observational Study [resa] 0.0005238652244
Lipoproteins [aapp, bacs] 0.000523818394524
Adjustment [inbe] 0.000522720681088
Protection [fndg] 0.000521266829983
Cl - [elii] 0.000520383374321
Limited [ftcn] 0.000519789262722
Link [inpr] 0.000519263284634
Sample [sbst] 0.000518348950241
Medications [phsu] 0.00051738388772
chronic [tmco] 0.000516850796927
measurements [ftcn] 0.000515442279718
Decade [qnco] 0.000515198039936
Inflammatory [ftcn] 0.000515169545856
Second [qnco] 0.000513634130588
Triglyceride [bacs, lipd] 0.000511368945006
account [idcn] 0.000510802936743
Involved [ftcn] 0.000509770260185
Goal [inpr] 0.000507329633361
Effectiveness [qlco] 0.000505589886114
Primary Prevention [topp] 0.000505129427436
Isoflavones [orch, phsu] 0.00050450069303
Burden [idcn] 0.000503865304037
Adults [aggp] 0.000502923434228
Modification [ftcn] 0.000501327520344
mg day [qnco] 0.000501071504172
Hospitalization [hlca] 0.000499554253353
Measures [qnco] 0.000498472739154
weight [orga] 0.000498395946821
III [inpr] 0.000497732941617
Select [acty] 0.000497438848185
Radiation [npop] 0.000497197023987
Risk factor [qnco] 0.000497177033809
Regimen [topp] 0.000496675937283
Third [qnco] 0.000496121437381
Bone Mineral Density [clna] 0.000496003444503
Small [qnco] 0.000495618015909
Estimated [qnco] 0.000495527956341
Hypothesis [idcn] 0.000495433356838
mg/L [qnco] 0.000493621375029
Point [qnco] 0.000493000504044
topic9
Estrogen [horm, phsu, strd] 0.0045948770979
C-reactive protein [aapp, imft] 0.00395289644832
N NOS [aapp, imft] 0.00311712744372
Men [popg] 0.00255641270425
placebo [topp] 0.00252205738577
Stroke [dsyn] 0.00227326998977
Subject [grup] 0.00226338173209
mg% [qnco] 0.00221224446776
Incidence [qnco] 0.00221128832396
Measured [qlco] 0.00209764891004
Individual [popg] 0.00208234275089
coronary [bpoc] 0.00195509729922
R- [spco] 0.00195436315348
Early [tmco] 0.0019359965096
Recent [tmco] 0.00192666301369
Current [tmco] 0.00192013611526
Blood Pressure [orgf] 0.00190119357125
Diabetes [dsyn] 0.00188734810659
Benefit [qnco] 0.00188037674327
randomized [resa] 0.00185429102117
Cardiac [bpoc] 0.0017937455378
Dose [qnco] 0.00174583539885
Received [qlco] 0.00169100708012
Decreased [qnco] 0.00168753074708
Confidence Interval [qnco] 0.00168248368553
Oral [spco] 0.00168002916643
Cholesterol [bacs, strd] 0.00167284362363
Association [menp] 0.00166710901696
Non [ftcn] 0.00164600963392
Myocardial Infarction [dsyn] 0.00162864256835
Total Cholesterol [lbpr] 0.00161515896857
Receive [qlco] 0.00159273096923
Breast Cancer [neop] 0.00159169196641
Endothelial [tisu] 0.00158797345786
IMPACT [gngm] 0.00158340104098
Death [orgf] 0.00157082367432
Change [ftcn] 0.0015529299972
High Risk [qlco] 0.00154742909553
Aged [orga] 0.00153323081031
Common [qnco] 0.00152435330506
findings [ftcn] 0.00151815570761
Decrease [qlco] 0.00151272602234
Elderly [popg] 0.00150210198022
Drug [phsu] 0.00150179100218
Quality [qlco] 0.00148324288497
Drugs [phsu] 0.00147910290375
Survival [acty] 0.00147076614084
Menopause [phsf] 0.00146917634203
Plus [qlco] 0.00145941529854
Induced [ftcn] 0.00142603340118
Assess [acty] 0.00141599699952
Raloxifene [orch, phsu] 0.00141030877673
Statins [orch, phsu] 0.00140030785169
Profile [lbpr] 0.00139961909766
Several [qnco] 0.00137997567945
Medical [ftcn] 0.00137788498961
Combined [qlco] 0.00137668793181
vascular [bpoc] 0.00136470778642
Users [humn] 0.00136413858439
Lipid [lipd] 0.00136169709607
low [qlco] 0.00135587084975
Body Mass Index [diap] 0.0013407356941
Heart [bpoc] 0.00131244605974
function [phsf] 0.00131236998912
Progestin [horm, phsu, strd] 0.00129586303645
Evaluated [ftcn] 0.00129244152452
Old [tmco] 0.00128343826195
Addition [ftcn] 0.00128176008602
radiotherapy [inpr] 0.00126705049755
Atherosclerosis [dsyn] 0.00126148737521
median [spco] 0.00126134842742
Improvement [cnce] 0.00125265862085
Complications [patf] 0.00124493157636
Plasma [bdsu] 0.00123967090777
mg dl [qnco] 0.00123194927173
ischaemic heart disease [dsyn] 0.00122511669313
Diagnosis [fndg] 0.00122393752651
Osteoporosis [dsyn] 0.00121629755249
coronary artery disease [dsyn] 0.00120611694704
Possible [qlco] 0.00120297183393
lowering [spco] 0.0011973055449
weeks [tmco] 0.00118962753112
Reported [inpr] 0.00117911188146
Take [hlca] 0.00117211356631
Assessed [acty] 0.00114326259105
Known [qlco] 0.00114263922096
Acute myocardial infarction [dsyn] 0.00113629602566
Similar [qlco] 0.00113434425696
Well [qlco] 0.00113376670724
Cancer [neop] 0.00113266491744
Equal [qlco] 0.00112797520993
Concentrations [menp] 0.00112490135496
Therapeutic [topp] 0.00112289943421
Combination [qlco] 0.0011216582804
Life [idcn] 0.00111568959874
Marker [clna] 0.00111567398697
intervention [hlca] 0.00111112277955
Agent [chvf] 0.00111032941349
Serum [bdsu] 0.00110526734285
Predictor [idcn] 0.00110145819176
acute [tmco] 0.00109799509265
Purpose [ftcn] 0.0010941423608
Independent [idcn] 0.00109406021503
Target [ftcn] 0.00109143788357
Prevalence [qnco] 0.00109028147013
Provide [acty] 0.00108966057807
Statin [orch, phsu] 0.00108902822793
WHI [inpr] 0.00107929521448
APPEAR [qlco] 0.0010779732889
Values [qlco] 0.00107353832392
Risks [qlco] 0.00106857281856
Large [qnco] 0.00106755721357
Range [qnco] 0.00106710150356
Null [qnco] 0.00105931031419
Hormone Therapy [topp] 0.00103875983839
Cases [ftcn] 0.00103668701693
Odds Ratio [qnco] 0.00103627815608
development [phsf] 0.00103316974138
Events [evnt] 0.00103277683227
Response [orga] 0.0010318679207
Sex [orgf] 0.00102517631871
PREVENT [phsu] 0.0010218802269
Alone [qnco] 0.00101846519013
Young [tmco] 0.00101520537298
symptoms [ftcn] 0.0010058774621
Drug Therapy [topp] 0.000998635503027
Parameters [fndg] 0.000997312204973
Additional [ftcn] 0.000995556627169
Available [ftcn] 0.000990241622039
condition [dsyn] 0.000985196185804
Smoking [inbe] 0.000984529021863
Inflammation [patf] 0.00097950806752
Presence [topp] 0.000978527900314
Literature [inpr] 0.000972398232743
Model [inpr] 0.000970802002034
Heart disease [dsyn] 0.000956656902215
Morbidity [qnco] 0.00095620686685
Relationship [qlco] 0.000953108242371
Initiative [menp] 0.000949669043306
Primary [qlco] 0.000945116549224
Various [irda] 0.000943934662383
Mechanisms [ftcn] 0.00094115503722
Reducing [qlco] 0.000939676485115
Secondary Prevention [topp] 0.000937544952102
investigated [ftcn] 0.00093680210543
Safety [hcpp] 0.00093303696568
Established [qlco] 0.000933028450669
C-reactive protein level [lbpr] 0.000928627983399
Article [inpr] 0.000925837838943
Dependent [qlco] 0.000923530119542
Overall [inpr] 0.000918533049154
Conduct [inbe] 0.000917541386334
Aspirin [orch, phsu] 0.00091643091005
Specific [qlco] 0.000914818103155
Following [tmco] 0.000911879837933
Guidelines [inpr] 0.000909523794312
Make [ftcn] 0.000901354364422
Need [qlco] 0.000897481545681
Estrogens [horm, phsu, strd] 0.000895236866615
Heart failure [dsyn] 0.000892756554821
Elevated [qlco] 0.000888338289702
Main [qlco] 0.000887340703781
System [ftcn] 0.000884438388495
Copyright [inpr] 0.000882651936521
LTD [ortf] 0.000877668992125
medroxyprogesterone acetate [horm, phsu, strd] 0.000875466215599
cardiovascular risk factor [dsyn] 0.000872787809483
Obesity [dsyn] 0.000871601014375
Approach [spco] 0.000865378897581
cardiovascular events [fndg] 0.000858835107057
Likely [qlco] 0.000856774154878
mg day [qnco] 0.000856155912204
Estradiol [horm, phsu, strd] 0.000855569027307
Evaluation [ftcn] 0.000853105190176
Improved [qlco] 0.000851505273443
Concentration [menp] 0.000850671741532
practice [menp] 0.000848671825429
Duration [tmco] 0.000844331350545
mediated [socb] 0.000844060859616
Transdermal [ftcn] 0.000842282832195
Index [inpr] 0.000839209155737
tibolone [phsu, strd] 0.00083591333172
Five [qnco] 0.00083231003536
Adjusted [ftcn] 0.00083014615386
Information [idcn] 0.000827857915755
homocysteine [aapp, bacs] 0.000823478240329
Recently [tmco] 0.000822989396473
Cost [qnco] 0.000822464951902
Severe [qlco] 0.000821710791652
Human [humn] 0.000819800797671
Benefits [qnco] 0.000818198975353
setting [ftcn] 0.00081484177815
Affect [menp] 0.000810284569424
GIVEN [cnce] 0.00080935059902
Previous [tmco] 0.000807282931979
Clinical Trials [resa] 0.000801855047207
Relative Risk [qnco] 0.000796178152588
Recommended [idcn] 0.000794237074204
Identified [qlco] 0.000790400495351
Estrogen Replacement Therapy [topp] 0.000789575261835
Ireland [geoa] 0.000786680766506
activity [dora] 0.000783606358315
Percent [qnco] 0.000782691810106
I- [inch] 0.000780301817352
Assessment [hlca] 0.000778002455432
Atherogenesis [patf] 0.000777814425806
Continuous [idcn] 0.000774607587488
Type [qlco] 0.000774142041035
Modification [ftcn] 0.000774084296935
Cholesterol, LDL [bacs, strd] 0.000770214865399
Administration [ocac] 0.000769679985001
Part [spco] 0.000768730726016
g% [qnco] 0.000768249009613
Fasting [fndg] 0.000768054028181
Short-term [tmco] 0.000766760634686
strategies [menp] 0.000766692935631
Status [qlco] 0.000766271324211
Female [fndg] 0.000761353242829
In [qnco] 0.000761187218748
Small [qnco] 0.000760289596219
Now [tmco] 0.000758992520785
Exercise [dora] 0.000758125868904
Average [qnco] 0.000754027318352
Action [ftcn] 0.000752283520775
Children [aggp] 0.000750713641368
Fibrinogen [aapp, bacs, phsu] 0.000750369024062
Low Density Lipoprotein Cholesterol [bacs, strd] 0.000746402664853
variables [qlco] 0.000742854308298
Insulin [aapp, horm, phsu] 0.000742840895096
Sclerotherapy [topp] 0.000741280489971
Issue [fndg] 0.000741068650646
Support [medd] 0.000739864894775
side effects [ftcn] 0.000739427127732
High Density Lipoprotein Cholesterol [bacs, lipd] 0.000737600672014
H+ [elii] 0.000736870929105
Flow [npop] 0.000734411492288
account [idcn] 0.000732357676684
Relative [famg] 0.00073081301022
Hormone [horm] 0.000730579202293
Diet [food] 0.000729980981489
Endothelium [tisu] 0.000725264006789
Observational Study [resa] 0.000725163138059
Life Style [socb] 0.000723875943249
Dietary [food] 0.000723726241706
considered [idcn] 0.000722086808808
Adult [aggp] 0.000720185099558
Better [qlco] 0.000715371443008
prospective [resa] 0.000714879531481
III [inpr] 0.000714753795735
influential [idcn] 0.000713752272578
Sample [sbst] 0.0007101053819
Physicians [prog] 0.000709711474308
Needed [qlco] 0.000708102604257
Care [acty] 0.000707822649003
premenopausal [tmco] 0.000706700209752
Published [ocac] 0.000704370888844
Associations [menp] 0.000703243602797
Triglycerides [bacs, lipd] 0.000698596435794
HRT [topp] 0.000698491398429
Future [tmco] 0.000697697361281
Risk factor [qnco] 0.000697265087898
Dyslipidaemia [dsyn] 0.000696216534675
regimens [inpr] 0.00069568265484
Help [socb] 0.000693607325993
Interaction [ftcn] 0.000692760963371
month [tmco] 0.000692386404889
Daily [tmco] 0.000691249682631
Control Group [grup] 0.000689462547374
national [inpr] 0.000685708499423
participants [popg] 0.000684306250097
Concern [idcn] 0.000683557053832
Diseases [dsyn] 0.000682396770704
Seen [qlco] 0.000680139673411
Protection [fndg] 0.000678095802217
Occur [acty] 0.000675582990366
heart rate [clna] 0.000671636048511
Strong [qlco] 0.000671070120578
Question [inpr] 0.000666477457363
Examined [fndg] 0.00066228831862
History [ocdi] 0.000662126896646
Characteristics [qlco] 0.000661081052754
rosuvastatin [orch, phsu] 0.000652865934097
Variability [cnce] 0.000650510499633
Contribute [acty] 0.000650477718993
Inhibition [menp] 0.000648814972006
Currently [tmco] 0.000646736346846
Increasing [ftcn] 0.00064451413111
investigate [ftcn] 0.000639126300588
Beta-Blockers [phsu] 0.000638946734533
diabetic [fndg] 0.000638847903806
Low dose [qnco] 0.000637926680084
Consecutive [qlco] 0.000633809408968
Very [qlco] 0.000633232733385
Progesterone [horm, phsu, strd] 0.000630593269932
Surgery [bmod] 0.000629192995861
Multiple [qnco] 0.000628166271324
Relevant [qlco] 0.000626594536178
Hospital [hcro, mnob] 0.0006265860954
prescribed [hlca] 0.000621962212084
Same [qlco] 0.000620306219604
Chemoprevention [topp] 0.000620230553846
Atrial Fibrillation [patf] 0.000615926079116
statistically significant [qnco] 0.000613197380689
Isoflavones [orch, phsu] 0.000606301328245
Ischaemic [ftcn] 0.000604787159929
Correlated [qlco] 0.00059991422794
reductions [npop] 0.000596222472909
Revealed [qlco] 0.000594593760586
Equine [mamm] 0.000593576375513
Conjugated estrogen [horm, phsu, strd] 0.00059332229537
Medications [phsu] 0.000591832021493
Long [qlco] 0.000589324324899
Familial hypercholesterolaemia [dsyn] 0.00058920968194
Carotid [bpoc] 0.00058689315453
Science [ocdi] 0.000585997549566
Leading [tmco] 0.000585943288669
chronic [tmco] 0.000582785980352
Beta [plnt] 0.000582152852745
???lead [elii, hops] 0.000581512539703
Gender [orga] 0.000580777890883
Screening [hlca] 0.000576829950446
Protein [aapp, bacs] 0.000576582780281
Select [acty] 0.00057162577426
General [spco] 0.000570478431995
Measure [qnco] 0.000567768053949
Four [qnco] 0.000567090794981
Third [qnco] 0.000566441574413
Metabolic syndrome [dsyn] 0.000565791733425
Normal [qlco] 0.000565214262928
Method [inpr] 0.000563909970638
adverse effects [ftcn] 0.000563430641255
Understanding [menp] 0.000561306252787
Expression [topp] 0.000560079011703
mmHg [qnco] 0.000559756612887
Test [lbpr] 0.000556454227086
Cost Effectiveness [qnco] 0.000556145875801
hypertensive [fndg] 0.00055576079784
Appropriate [qlco] 0.000555481088168
Lipid-lowering therapy [topp] 0.000554658228169
TREAT [ftcn] 0.00055458410591
DOUBLE BLIND [resa] 0.000553958258202
Link [inpr] 0.00054463733861
progression [patf] 0.000543666184895
Modified [ftcn] 0.00054365734817
Calcium [bacs, elii, phsu] 0.000543599986244
Cardiovascular Diseases [dsyn] 0.000543312714726
Compare [acty] 0.000541290546258
Dilation [patf] 0.000537995733189
mmol/L [qnco] 0.000537564798379
Treatments [topp] 0.000536296963977
objectives [inpr] 0.000535437101627
Fatal [qlco] 0.000530795427243
Prognosis [hlca] 0.000530074386493
mg/L [qnco] 0.000528032860448
lack [qlco] 0.000527969953766
Age-Years [tmco] 0.000527178304297
search [inpr] 0.00052715112196
Moderate [qlco] 0.000526939340725
Hypercholesterolaemia [dsyn] 0.000526023137294
Triglyceride level [lbtr] 0.000525995544337
Estimated [qnco] 0.000525463579037
Effectiveness [qlco] 0.000524693600262
deaths [orgf] 0.000521828864264
Often [tmco] 0.000518069894589
Single [popg] 0.000517904625134
Defined [cnce] 0.000517622449901
Mechanism [ftcn] 0.000516717679057
Favorable [qlco] 0.000515333952829
Six [qnco] 0.000514417604744
placebo-controlled [resa] 0.000513791470154
Class [inpr] 0.000513783903711
soy [food] 0.00051361530975
Ratio [qnco] 0.000513369323354
Arterial [bpoc] 0.000513343878504
Lipids [lipd] 0.000512913140339
Low density lipoprotein [aapp, bacs, lipd] 0.000511356022333
recommendations [idcn] 0.000510887815684
Novel [tmco] 0.000510170374175
Triglyceride [bacs, lipd] 0.000510153927367
Hypothesis [idcn] 0.000509874000616
Adjustment [inbe] 0.000509645424313
Angiotensin-Converting Enzyme Inhibitors [phsu] 0.000508576160146
High density lipoprotein [aapp, bacs, lipd] 0.000507675429301
Alternative [cnce] 0.000507321385764
Glucose [bacs, carb, phsu] 0.000507201100013
Record [inpr] 0.000505991268464
End [spco] 0.00050548850289
Direct [qlco] 0.000505458834048
patient care [hlca] 0.000504683666397
Haemodialysis [topp] 0.000502985650225
rats [mamm] 0.000502971006809
Compound [qlco] 0.000501948473233
properties [qlco] 0.000500470661148
Venous malformation [anab] 0.000498610901971
Negative [qlco] 0.000496603829665
Correlation [qlco] 0.000495567070645
Required [ftcn] 0.000495007878261
plasma concentration [qnco] 0.000494265464975
Adhesion Molecule [aapp, bacs] 0.00049286545654
days [tmco] 0.000491868840179
